

SYMPOSIUM

PROCEEDINGS



GULF COAST
VETERINARY
SPECIALISTS



THANK YOU

TO OUR GENEROUS SPONSORS!

PLATINUM



GOLD



SILVER



BRONZE



7:00 AM – 8:00 AM REGISTRATION & BREAKFAST | SPONSOR TABLES OPEN



8:00 AM - 8:10 AM
OPENING REMARKS
FREDRICK CANTOR | HOSPITAL DIRECTOR



8:10 AM - 9:05 AM
DISTAL LONG-BONE FRACTURES: R U READY TI-BI-AFIXED?
DR. PHILIP ALLEN | SURGERY



9:05 AM - 10:00 AM
BETWEEN TWO INTERNISTS: FREQUENTLY ASKED CONSULTS
DR. PAUL MANINO | INTERNAL MEDICINE

10:05 AM – 10:25 AM MORNING BREAK | SPONSOR TABLES OPEN



10:25 AM - 11:20 AM
BETWEEN TWO INTERNISTS: FREQUENTLY ASKED CONSULTS
DR. DANIEL JARDES | INTERNAL MEDICINE



11:20 AM - 12:15 PM
BACKYARD CHICKEN MEDICINE: WHAT THE CLUCK DO I NEED TO KNOW?
DR. SUSAN BALEY | AVIAN & EXOTICS

12:20 PM – 1:20 PM LUNCH | SPONSOR TABLES OPEN



1:20 PM - 2:15 PM
DISCOSONDYLITIS: BRUCIE IS NOT YOUR FRIEND
DR. CARLEY GIOVANELLA | NEUROLOGY



2:15 PM - 3:10 PM
SEPSIS WON'T HESITATE. WILL YOU?
DR. HERNAN ANGULA-BRACHO | CRITICAL CARE

3:15 PM – 3:35 PM AFTERNOON BREAK | SPONSOR TABLES OPEN



3:35 PM - 4:30 PM
SURGICAL INTERVENTION OF BRACHYCEPHALIC [OBSTRUCTIVE] AIRWAY SYNDROME
DR. KRISTIN COLEMAN | SURGERY



4:30 PM - 5:15 PM
DIAGNOSING AND APPROACH TO TREATMENT FOR DIFFERENT TYPES OF CORNEAL ULCERS
DR. ROBIN SANKEY | OPHTHALMOLOGY

5:15 PM – 5:30 PM CLOSING REMARKS

7:00 AM – 8:00 AM REGISTRATION & BREAKFAST | SPONSOR TABLES OPEN



8:00 AM - 8:10 AM
OPENING REMARKS
FREDRICK CANTOR | HOSPITAL DIRECTOR



8:10 AM - 9:05 AM
PRACTICAL TIPS FOR BLOOD TRANSFUSIONS
DR. MELISSA GARCIA-LACAZE | CRITICAL CARE



9:05 AM - 10:00 AM
FELINE PANCREATITIS
DR. MELANIE PUCHOT | INTERNAL MEDICINE

10:05 AM – 10:25 AM MORNING BREAK | SPONSOR TABLES OPEN



10:25 AM - 11:20 AM
CANINE AND FELINE PEMPHIGUS FOLIACEUS
DR. KARIN BEALE | DERMATOLOGY



11:20 AM - 12:15 PM
DEGENERATIVE VALVE DISEASE: PRACTICAL GUIDE MANAGEMENT
DR. ERIC OWENS | CARDIOLOGY

12:20 PM – 1:20 PM LUNCH | SPONSOR TABLES OPEN



1:20 PM - 2:15 PM
ORTHOPEDIC PROBLEMS IN GENERAL PRACTICE
DR. KYLE PFEIFER & DR. KATIE PANSINI | DIAGNOSTIC IMAGING



2:15 PM - 3:10 PM
CARING FOR THE MOST CRITICAL PATIENTS FIRST: THE ART OF TRIAGE
DR. RHONDA DIXON | EMERGENCY

3:15 PM – 3:35 PM AFTERNOON BREAK | SPONSOR TABLES OPEN



3:35 PM - 4:30 PM
OPIOIDS
DR. KATHERINE MCIVER | ANESTHESIA



4:30 PM - 5:15 PM
MEDIAL PATELLAR LUXATION
DR. NATHAN SQUIRE | SURGERY

5:15 PM – 5:30 PM CLOSING REMARKS

TABLE OF CONTENTS

LECTURE SCHEDULE	3
MEET THE SPEAKERS	3
PHILIP ALLEN, DVM, DACVS	6
DISTAL LONG BONE FRACTURES: R-U READY TI-BI AFIXED?.....	
PAUL MANINO, DVM DACVIM, DANIEL JARDES DVM DACVIM.....	42
BETWEEN TWO INTERNISTS- FREQUENTLY ASKED CONSULTS.....	
SUSAN BAILEY, DVM, DABVP.....	66
BACKYARD CHICKEN MEDICINE: WHAT THE CLUCK DO I NEED TO KNOW?.	
CARLEY GIOVANELLA, DVM, DACVIM (NEUROLOGY).....	80
DISCOSPONDYLITIS: BRUCIE IS NOT YOUR FRIEND.....	
HERNAN ANGULA-BRACHO, DVM, MVZ,ESP.....	93
SEPSIS WON'T HESITATE. WILL YOU?.....	
KRISTIN COLEMAN, DVM, MS, DACVS.....	111
SURGICAL INTERVENTION OF BRACHYCEPHALIC [OBSTRUCTIVE] AIRWAY SYNDROME.....	
ROBIN SANKEY, DVM, DACVO.....	135
MELISSA GARCIA-LACAZE, DVM, DACVECC.....	149
PRACTICAL TIPS FOR BLOOD TRANSFUSIONS.....	
MELANIE PUCHOT, DVM, DACVIM.....	162
FELINE PANCREATITIS.....	
KARIN BEALE, DVM, DACVD.....	177
CANINE AND FELINE PEMPHIGUS FOLIACEUS.....	
ERIC OWENS, DVM, DACVIM (CARDIOLOGY).....	198
DEGENERATIVE VALVE DISEASE: PRACTICLE GUIDE MANAGEMENT.....	
KATIE PANSINIE, DVM, KYLE PFEIFER, DVM.....	221
ORTHOPEDIC PROBLEMS IN GENERAL PRACTICE, INCLUDING RADIOGRAPHIC ACQUISITION/POSITIONING AND INTERPRETATION.....	
RHONDA DIXON, DVM.....	239
CARING FOR THE MOST CRITICAL PATIENTS FIRST: THE ART OF TRIAGE.....	
KATHERINE MCIVER, DVM.....	250
OPIOIDS.....	
NATHAN SQUIRE, VMD, MS.....	264
MEDIAL PATELLAR LUXATION.....	
EXHIBITOR GUIDE.....	277

SURGERY



PHILIP ALLEN
DVM, DACVS

Dr. Philip Allen obtained his Doctorate of Veterinary Medicine from Kansas State University. He then spent a year performing a rotating medicine/surgery internship at Tufts University. Following his internship, Dr. Allen traveled to Minneapolis to complete a three-year surgical residency at the University of Minnesota. Dr. Allen became board certified by the American College of Veterinary Surgeons in 2019. Prior to joining GCVS in 2019, Dr. Allen worked as a surgeon at a specialty hospital in Kansas City. Dr. Allen's surgical interests include minimally invasive surgery (laparoscopy, thoracoscopy, fracture repair), joint replacement therapy, and interventional radiology procedures.



PHILIP.ALLEN@GCVS.COM
713-693-1111

Tibial Fractures & Surgical Approach to the Tibia

Philip Allen DVM, Diplomate ACVS-SA
Gulf Coast Veterinary Specialists
Houston, TX



1

Incidence


- 10-20% fractures
- 50% occur in immature patients
- Majority are diaphyseal
- Concurrent fibular fracture
 - Rarely repaired



2

Tibial Anatomy

- **Anatomy**
 - Sigmoid shape on the frontal plane
 - Nominal soft tissue envelope medially
 - Proximally shaped like a triangle
 - Distally cylindrical
- Quadriceps insertion for stifle extension
- Fibula important for lateral collateral ligaments of stifle and tarsus



3

Patient Assessment


- Complete physical exam
 - HBC common cause of tibial fx
 - Cardiovascular system
 - Urinary bladder
 - Other orthopedic injury
- 2 view radiographs affected bone
 - Craniocaudal & mediolateral



4

Fracture Pattern


- Simple Transverse
- Oblique
 - Short
 - Long
 - Spiral
- Butterfly
- Comminuted



5

Open Fractures

- Common in the tibia
 - Limited surrounding soft tissue
- Contamination and vascular compromise
 - Increased infection risk
 - Delayed bone healing



Gun Shot Injury

6


Methods of Fracture Stabilization

- Bone plate
- Bone plate with IM pin
- IM pin with cerclage wire
- External fixator
 - Linear
 - Circular
- Interlocking nail




7

Forces Acting on a Fracture




9

Forces Acting on a Fracture



10



11

Plate-Rod Construct

- Addition of an IM pin to a bone plate construct
- Decreases stress on plate
- Increases fatigue life of plate
- “Two-beam” system
- IM pin ~ 40% canal diameter
 - Interferes with screw insertion

12

Reduction in Plate Strain by Addition of an Intramedullary Pin



Hulse D, Hyman W, Nori M, et al.
 Veterinary Surgery, 1997

- Femoral gap model
 - Bridge plate
 - Bridge plate and IM pin
- Addition of rod decreased stress by 1/2 in plate-rod construct
- Implant fatigue life increased 10x

13


Plate-Rod

- Commonly utilized for tibial fx
- Pin resists bending
- Plate resists axial collapse and rotation
- Increased construct stiffness
 - Increased AMI




14

Decision Making





Compression Neutralization Bridging



15

Compression Plating


- Application
 - Simple transverse
 - Short Oblique
- Bone segments compressed
- Reconstructed bone column resists the majority of forces acting on fracture



16

Neutralization Plating

- Application
 - Long oblique
 - Butterfly
- Compression provided by screws
 - Cerclage wire
- Bone splinting provided by plate.




GC VLS GULF COAST VETERINARY SPECIALISTS

17

Neutralization Plating

- Load sharing
 - Bone plate
 - Reconstructed bone column



GC VLS GULF COAST VETERINARY SPECIALISTS

18

Bridging Plate

- Application
 - Comminuted
- Major bone segments aligned and stabilized
- Gap at fracture site




GC VLS GULF COAST VETERINARY SPECIALISTS

19

Bridging Plate

- Bone column not reconstructed
- Plate bears load across fracture site
 - No load sharing



20

Pre-Op Planning

- Radiographs
- Implant selection
 - Size & system
- Plate pre-contouring



21

Pre-Operative Radiographs

- Orthogonal views
- Affected & contralateral
- Positioning critical
 - Anatomic landmarks
- Magnification marker




Contralateral


22

Implant Selection

- Locking vs. non-locking
 - Locking preferred for bridging
- Implant size
 - Screw diameter
 - Plate length
 - Span majority of bone
- IM pin
 - < 40% medullary diameter




The image shows two locking plates and two non-locking screws. The locking plate on the left is shorter and has five locking holes. The locking plate on the right is longer and has six locking holes. The non-locking screws are shown next to their respective plates, with the text 'vs.' between them.




23

Pre-Operative Planning




The image shows two diagrams of a femur. The left diagram is a lateral view with two green lines indicating the planned incision sites. The right diagram is a medial view with a white line representing the planned intramedullary nail and several orange arrows pointing to the planned locking screw sites.




24

Patient Positioning

- Dorsal recumbency
- Rear end at edge of table
- Table tilted down caudally
- Vacuum bag



The image shows a dog lying on its back on a green table. A person is visible in the background, and a vacuum bag is placed under the dog's rear end.



25


Patient Positioning



26

Patient Preparation


- Clip limb from hip to hock
- Aseptic scrub
- Duraprep
- Adhesive drape



27

Surgical Approach


- Medial approach for all fractures
- Landmarks
 - Medial tibial condyle
 - Medial malleolus
- Incision straight or curving cranially in middle
- Neurovascular bundle
 - Saphenous A,V,N



28

Reduction Techniques


- Direct, open reduction
 - Anatomic reconstruction
- Indirect reduction
 - Limb alignment
 - Joint above and below fracture
 - Fracture not anatomically reconstructed



29


Direct Reduction Strategies

- Open surgical approach
- Bone holding forceps grip primary segments
- Distract and reduce
- In comminuted fracture work on 2 segments at a time



30

Reduction Tools



31

Reduction Tools

AO Point to Point Reduction Forceps




Clamshell Reduction Forceps- Speedlock



32

Direct Reduction

- Fracture has 2-4 fragments
- Repair 2 fragments at a time
- Interfragmentary compression
 - Lag screws, cerclage
- Primary fixation




Direct reduction



33

Indirect Reduction Strategies


- Principle: Traction restores length, soft tissue tension reduces fragments
 - Applicable to comminuted fractures
- Hanging limb technique
- IM pin reduction assistance
- Temporary external fixator +/- gear



34

IM Pin Reduction

- Pin inserted normograde
- Guides fracture reduction
- Distract bone to proper length
 - Blunt distal pin tip
- Cut short or countersink for plate-rod




GC VET SPECIALISTS

35

Tibia Technique

- Approach to tibial plateau
 - Medial or lateral
- Insert pin cranial to intermeniscal ligament
- Drive pin distally, medially, and slightly caudally
 - Reduction forceps on shaft
- Blunt pin tip to prevent cortical penetration




GC VET SPECIALISTS

36

Tibial IM Pin Technique


- Insertion can be challenging
- Premature cortical penetration
 - Lateral
 - Cranial
- Tibial morphology
 - Recurvatum
 - Sigmoid shape



GC VET SPECIALISTS

37


Tibia



38



Temporary Ex-Fix

- Simple 2 ring circular fixator construct
- Single wire proximal and distal
- Wires parallel with joint surfaces
- Distract and align bone segments
- Remove after plate application



39


Temporary Ex-Fix



40

Stepwise Tibial Fx Repair


- Evaluate radiographs
 - Develop plan
- Surgical approach
- Reduce fracture
- Insert IM pin
- Apply bone plate
- Close



41

Case Example: 10 y.o. M Beagle HBC Radiograph Evaluation

- Mid diaphyseal
- Comminuted
- Open
 - Subcutaneous emphysema
- Minimally displaced



43

Surgical Plan

- Minimize disruption of fracture site
- Indirect reduction
 - Pre-contoured plate
- Bridge plate
 - Plate-rod
 - Possible delayed healing



44

Surgical Approach & Reduction


- Full approach to medial shaft of tibia
- No disruption of fracture site
- Indirect reduction
 - Manual traction
 - Normograde IM pin insertion
 - Blunt pin tip



45

Bone Plate Application

- Locking plate selected
 - Pre-contoured
 - Contralateral limb radiographs
- Plate application improves fracture alignment




46


Temporary Stabilization With K-wires




47



48



49



50

Interlocking nails

- Initially used simple intramedullary nails
- Current locked nails: union rates >90% in humans (Wiss, J Bone Joint Surg Am, 2001):
- Common characteristics
 - Solid intramedullary rods
 - Transverse holes (cannulations)
 - Locked in place with bone screws or partially threaded bolts



51

Interlocking nails

- Initially used simple intramedullary nails
- Common characteristics
- Benefits:
 - Greater resistance to torsional forces than plates and standard IM pins (Kyle, Clin Orthop Rel Res 2001)
 - Superior fatigue resistance, bending stiffness compared with standard plate fixation (Mauc, Vet Comp Orthop Traumatol 1995)
 - AMI of a solid 6-mm diameter ILN is almost 4 times that of a 3.5 mm dynamic compression plate (flat surface) (Bernarde, Vet Surg 2001)



52

Concerns:

- Weaker in mediolateral bending d/t AMI
 - smaller in a bending plane parallel to the nail hole = stress concentration
- Screw failure - initially larger holes (3.5, 4.5), now 2.7, 3.5
 - Increased nail fatigue life 8x, decreased screw AMI by 40%
- Switched to partially threaded bolts



53

Interlocking nails

- Initially used simple intramedullary nails
- Common characteristics
- Currently available products (US):
 - Innovative Animal Products - Original Interlocking Nail System
 - BioMedtrix - I-Loc Angle Stable ILN



54

Innovative ILN

- Modified Steinmann IM pin with single trocar point
- 4-, 4.7-, 6-, 8-mm
- 3- or 4- hole design
- Initially used screws, now use partially/cis threaded bolts
- 2-, 2.7-, 3.5-mm
- fixed length, cut to size




Figure 6. Interlocking bolts: 3.5 (A), 2.7 (B), and 2 (C) mm.



55

Innovative ILN

- 83% initial success (105 dogs)
- 10% nail breakage d/t fatigue failure





Figure 6. Interlocking bolts: 3.5 (A), 2.7 (B), and 2 (C) mm.



56

Biomedtrix I-Loc

- Hourglass profile IM pin
 - minimize damage to endocortices?
- Bullet tipped
 - minimize penetration into joint space
- Locking nail cannulations
 - self-centering, self-locking
 - threaded Morse taper
- Locking bolt
 - threaded conical central section
 - matches cannulation




57

Implantation technique

- Use temporary smooth locking posts
 - creates rigid frame between alignment guide and nail
- Trial nail for accurate length estimate
- Threaded cannulation can confirm appropriate drill placement




58



59

Toy Breed Considerations


- Relatively small medullary canal
- May be difficult to utilize IM pin/ plate-rod
- Small bone plates relatively weak
 - Stacked plates- not preferred
 - Double plating
- Consider bone graft



82

Proximal & Distal Tibial Fractures


- Philip Allen DVM, Diplomate ACVS
- Gulf Coast Veterinary Specialists
- Houston, TX



83

Immature Tibia

- Physes
 - Proximal
 - 40% growth in length
 - Distal
 - 60% growth in length
- Apophysis
 - Tibial tuberosity
 - Medial malleolus



85

Apophysis

- Normal bone outgrowth arising from a separate ossification center
- Fuses with primary bone over time
- Apophysis is site of tendon or ligament attachment
- Also called traction epiphysis
- Epiphysis is a component of a joint



86

Fracture Categories

- Immature patients
 - Physeal fractures
 - Salter Harris types
- Skeletally mature patients
 - Proximal & distal metaphyseal fractures




87

Physeal Fractures

- Salter Harris Classification
 - Five Types

Salter-Harris classification of physeal fractures



88

Proximal Physis Fractures

- Salter Harris I
 - Slipped physis
 - Epiphysis & apophysis remain together
 - Displace proximally & caudally
- Anatomic reduction
 - Preferred if possible
 - Open or minimally invasive



93

Proximal Physis Type I

- Stabilization options
 - Acute
 - Cross pins
 - Parallel pins through tuberosity
 - Chronic
 - Cross pins
 - Lag screw(s)



94

Reduction Techniques

- Open, direct reduction
 - Remove hematoma from fracture site
- Minimally invasive reduction
 - Acute time period
 - Often possible to obtain anatomic reduction



C-Arm Guided Reduction



95

Proximal Physeal Fx Reduction

- Point to point forceps on tuberosity
- Hyperextend stifle joint



96

Proximal Physis Stabilization


- Drive K-wire through apophysis
 - Center wire on segment
 - Direct caudal & distal
- Needle used to identify wire insertion site



Needle used to identify wire insertion site

97

Proximal Segment Stabilization



98


Insert Additional Wires

- Medial & lateral tibial plateau




99

Additional Wire Insertion




100

3 Wires Inserted




101

Cut Wires & Countersink




102

Post Op



103


4 Wks



104

Proximal Physis Fracture


- Salter Harris type I
- Separation of apophysis from epiphysis



105

Post Op

- Divergent K-wires
 - K-wire through cranial epiphysis
- Tension band on tuberosity
 - Chronic injury
 - Patient almost skeletally mature



106




4 Wk Post




Explanted 6 Wk Post


107



108



111



112

Tibial Tuberosity Avulsion


- Pins placed perpendicular to fracture line
- Tension band wire
 - Converts distraction forces to compression
- Closure of tuberosity growth plate



113

Biomechanics


- Tension band applies opposing force to muscle pull
- Opposing forces create compression



114

Biomechanics


- K-wires
 - Prevent rotation
 - Compression force directed along K-wires
 - Insert perpendicular to fracture line
- Orthopedic wire
 - Counters tension loads



115

Distal Physeal Fractures

- Salter Harris I, II, III, IV
- Repair options
 - Cross pins
 - Type I
 - Lag screws +/- plate
 - Type II, III, or IV



116


Distal Physeal Reduction

- Open, direct
- Minimally invasive




117

Reduction Techniques



Hyperflexion of tarsus helps achieve reduction




Army navy helps maintain reduction



118

K-Wire Insertion



119



Post Op

4 Wks




120

Distal Physeal Fracture


- Metaphysis, physis and epiphysis affected
 - Salter Harris type IV
- Anatomic reconstruction
- Rigid stabilization
- Plate and lag screws




121



122



123



124

Specialized Function Plates




May be utilized for proximal or distal tibial fractures



125

Post Op


- Double plating
 - At each fracture site
 - Increase number of screws per segment
- TPLO plate proximally



126

Pre Op Planning


- Midshaft diaphyseal fracture
- Distal metaphyseal minimally displaced fracture
- Implant type & location
- Determine location of physis



127

Post Op

- Double plating
- Cranial notched head T plate
- Medial LCP
 - Distal cortical screw
 - Angled to avoid growth plate
- Cerclage to control fissure lines



128

4 Wk Post

- Fractures healed by 4 wks
- Physis still open proximally
- Distal physis?



129

Thank you



130


INTERNAL MEDICINE

PAUL MANINO
DVM, DACVIM



Dr. Paul Manino, DVM, completed his veterinary degree at Louisiana State University in 2003. Following this, he undertook a one-year small animal medicine and surgery internship at Carolina Veterinary Specialists, NC. With five years of experience in emergency/critical care, he pursued a three-year small animal internal medicine residency, becoming board certified by the American College of Veterinary Internal Medicine in 2012.


Dr. Manino's expertise lies in liver disease, fungal disorders, and advanced laparoscopy and endoscopic-guided laser procedures. He currently heads the internal medicine department at GCVS. Beyond his professional commitments, Dr. Manino enjoys family time, cooking, and philanthropic endeavors as a 501st legion member.

 PAUL.MANINO@GCVS.COM
713-693-1111


DANIEL JARDES
DVM, DACVIM



Dr. Daniel Jarde received his bachelor's degree in organismal biology from the University of Kansas in 2007 and veterinary degree from Kansas State University in 2011. He completed a one-year rotating internship followed by a three-year residency in small animal internal medicine at Tufts University in Massachusetts. During his residency, his research was focused on acute kidney injury and chronic kidney disease. Dr. Jarde became board certified by the American College of Veterinary Internal Medicine in 2015. Dr. Jarde has a special interest in renal disease. In his spare time, he enjoys woodworking and assembling jigsaw puzzles with his family.

 DANIEL.JARDES@GCVS.COM
713-693-1111





Questions on Proteinuria

- How and when do I screen for proteinuria?
- Does the degree of proteinuria help me determine the etiology?
- What are the most common causes of proteinuria?



How and when do I screen for proteinuria?


- Typically clinically silent
 - Decreased appetite?
- An unexpected finding
 - Routine labs
 - During evaluation for an unrelated disease

Recommendations:

- All patients should have a urinalysis during their routine health screen every 6-12 months
- All patient should have a urinalysis performed at a time of illness
- Start with dipstick
- Urine protein to creatinine ratio for quantification (UPC)



Dipstick evaluation vs. UPC



- Dipstick = semi-quantitative
 - Not always significant
 - Altered by active sediment
- Recommendations:**
- Run UPC if:
 - 2+-3+ proteinuria
 - Persistent 1+ proteinuria > 4wks
 - Concurrent disease with high risk for proteinuria



Determining the cause of proteinuria

- Three key factors:
- Persistence
 - Proteinuria on repeated testing
 - Magnitude
 - The degree of proteinuria
 - Localization
 - Where in the kidney?



Determining the cause of proteinuria

Persistence

- Proteinuria on at least 2 occasions > 2 weeks apart
- Transient proteinuria
 - Fever
 - Steroids
 - Vasculitis

Magnitude (UPC)

- 0-0.2 normal
- 0.3-0.5 borderline
- >0.5 abnormal
- >2.0 more commonly seen with glomerular disease




Determining the cause of proteinuria

Pitfalls of UPC measurement:

- Up to 40% day to day variation
- Altered by stress level
- Sensitive to sample handling

Recommendations


- Pooled sample collected over 3 days
- Collected at home in a glass container or sterile urine container
- Refrigerated until dropped off



Determining the cause

Localization

- Pre-glomerular (systemic)
- Glomerular
- Post-glomerular (tubular)
 - Look for concurrent glucosuria



Determining the cause of proteinuria

Pre-glomerular (afferent arterioles)

- Hypertension
- Marked hyperglobulinemia
- Fever
- Vasculitis

Glomerular

- Immune-complex glomerulonephritis
- Amyloidosis
- Podocytopathies
 - Minimal change disease
 - Glomerulosclerosis
 - Steroid administration



Post-glomerular (tubular)

- Leptospirosis
- Toxicity
 - Including jerky treats
- Fanconi's syndrome
- Chronic kidney disease
- Acute kidney injury

Determining the cause of proteinuria

Diagnostic work up is ordered least to most invasive

Minimum database for all patients with elevated UPC

- Toxicity history (grapes, raisins, NSAIDs, jerky treats)
- Blood pressure
- CBC, Chemistry, Urinalysis
- Heartworm testing (causes immune-complex glomerulonephritis)
- Leptospirosis testing
- Protein electrophoresis if hyperglobulinemic



Determining the cause of proteinuria

If all normal/negative you have glomerular localization

Additional diagnostics:

- Biventricular imaging (chest radiographs/abdominal ultrasound)
- Vector-borne infectious disease testing (PCR and Serology; NCSU)
- Urine histoplasmosis testing
- Kidney biopsy



What are some guidelines for the management of megaesophagus?
What is a good ¹³¹I candidate?
Patient with a flare of IMT. How do I manage?
How do I best manage a dog with collapsing airway disease?
When do I need to be worried about increases in cholesterol/triglycerides?
Is laser lithotripsy a viable option to remove bladder stones?
What probiotic is best for dogs and cats?
Patient with suspected hyperadrenocorticism but normal LDDS.
What is next best step?
When/how to manage proteinuria in a dog?
Cat with suspected ureteral calculi. What are options for care?
Can I get some information of the new pancreatitis drug available?
How best to treat a case of histoplasma or heterobilharzia?
Cat with suspected FIP. Are there any new treatments?
How do I best incorporate the use of a wearable glucose monitor?



Questions on Proteinuria Treatment

- What patients do I treat?
- Are there any recent changes in treatment?
- What are the best management strategies for patients with concurrent hypertension?
- Are there treatment options for presumed immune-complex glomerulonephritis for a patient who is unable to get a biopsy?



What patients do I treat?

Persistence	Magnitude (UPC)
<ul style="list-style-type: none">• Proteinuria on at least 2 occasions > 2 weeks apart	<ul style="list-style-type: none">• 0-0.2 normal• 0.3-0.5 borderline• >0.5 abnormal• >2.0 more commonly seen with glomerular disease



Are there any recent changes in treatment?

Specific etiology treatment

Four mainstays of treatment:

- Dietary protein restriction
- Fatty acid supplementation
- Antithrombotic therapy
- *Inhibition of the Renin-Angiotensin-Aldosterone System (RAAS)*




Are there any recent changes in treatment?

Inhibition of RAAS

- Used to reduce protein loss
- Renoprotective effects
- Anti-hypertensive effects

Two categories of medications

- Angiotensin-converting enzyme inhibitors (ACE-I)
- Angiotensin-receptor blockers (ARB)



Are there any recent changes in treatment?

IRIS Canine GN Study Group 2013:

Drug	Indication	Initial Dose	Escalating Dose
Benazepril	Angiotensin converting enzyme inhibitor ^a	0.5 mg/kg PO q24h	Increase by 0.5 mg/kg/d to a maximum of 2 mg/kg PO per day. Can give q12h
Enalapril	Angiotensin converting enzyme inhibitor ^a	0.5 mg/kg PO q24h	Increase by 0.5 mg/kg/d to a maximum of 2 mg/kg PO per day. Can give q12h
Ramipril	Angiotensin converting enzyme inhibitor ^a	0.125 mg/kg PO q24h	Increase by 0.125 mg/kg/d to a maximum of 0.5 mg/kg PO per day. Usually give q24h
Imidapril	Angiotensin converting enzyme inhibitor ^a	0.25 mg/kg PO q24h	Increase by 0.25 mg/kg/d to a maximum of 5 mg/kg PO per day. Usually give q24h
Telmisartan	Angiotensin receptor blocker ^b	1.0 mg/kg PO q24h	Increase by 0.5 mg/kg once daily up to 2 mg/kg/d
Losartan	Angiotensin receptor blocker ^b	0.125 mg/kg/d in azotemic dogs 0.5 mg/kg/d in nonazotemic dogs	0.25 mg/kg/d in azotemic dogs 1 mg/kg/d in nonazotemic dogs

Are there any recent changes in treatment?

Inhibition of RAAS- Side effects

- Decreased appetite
- Increase in creatinine
- Hyperkalemia

Management strategies

- Drug holiday
- ECG monitoring (K>6.0)
- Dose/medication reduction



Are there any recent changes in treatment?

Dietary protein restriction

- Reduce the amount protein loss through the glomerulus and slow the progression of CKD
- Sodium restriction
- Works synergistically with RAAS inhibition to lower blood pressure



Are there any recent changes in treatment?

Fatty acid supplementation

- Lower the degree of proteinuria
- Delay the progression of chronic kidney disease

Sources

- Commercial kidney diets
- Additional supplementation
- Tufts Heart Smart-> Diet -> Nutrients -> Omega-3



Are there any recent changes in treatment?

Product Name	Company	Price/100 mg of EPA+DHA	Daily dose
Cats and Small or Medium-Sized Dogs			
CVS Fish Oil Concentrate Capsules (180 mg EPA and 120 mg DHA per softgel)	CVS Pharmacy	2¢	1 capsule per 10 pounds body weight
Large Dogs			
GNC Triple Strength 1500 (540 mg EPA and 360 mg DHA)	GNC	2¢	1 capsule per 30 pounds body weight
Nordic Naturals Ultimate Omega (325 mg EPA and 225 mg DHA)	Nordic Naturals	6¢	1 capsule per 18 pounds body weight
Simply Right Triple Strength Fish Oil (647 mg EPA, 253 mg DHA). Note: lower in DHA than other brands	Sam's Club	1¢	1 capsule per 35 pounds body weight
Solgar Omega-3 (360 mg EPA and 240 mg DHA per softgel)	Solgar	4¢	1 capsule per 20 pounds body weight
Twinkl Omega-3 (270 mg EPA and 180 mg DHA per softgel)	Twinkl	2¢	1 capsule per 15 pounds body weight
Liquids			
Vitamin Shoppe Omega-3 Fish Oil 800 EPA/500 DHA – liquid (800 mg EPA and 500 mg DHA per teaspoon). Note: lemon-flavored	The Vitamin Shoppe	2¢	1 teaspoon per 44 pounds body weight
Welactin Canine Liquid. Note: not independently tested	Nutramax	Variable	1 scoop per 48 pounds body weight
Welactin Feline Liquid. Note: not independently tested	Nutramax	Variable	1 scoop per 9 pounds body weight



Are there any recent changes in treatment?

Antithrombotic therapy

- Thromboembolism in as high as 25% with GN
- Due to loss of antithrombin III
- Little evidence for recommendation

Widely used options

- Aspirin 1-5 mg/kg daily
- Clopidogrel 2-3 mg/kg daily



Management of concurrent hypertension?

- Measurement of systolic blood pressure
- Risk of target organ damage
 - < 150 mmHg = no or minimal risk
 - 150-159 mmHg = low risk
 - 160-179 mmHg = moderate risk
 - >180 mmHg = high risk
- Multiple measurements needed to determine the risk



Management of concurrent hypertension?

Goals for moderate to high risk patients:

- Blood pressure < 150 mmHg
- Gradual reduction over weeks (except with crisis)
- Individualized treatment plan based on risk



Are there any recent changes in treatment?

Moderate risk

- Telmisartan at 1 mg/kg SID
- Low sodium diet

High risk

- If eating well Telmisartan at 1 mg/kg SID and
- Calcium channel blockage with Amlodipine at 0.2 mg/kg PO SID

Refractory cases: ACE-I or spironolactone



Treatment for immune-complex glomerulonephritis without biopsy?

Very common predicament:

- Refractory proteinuria with glomerular localization
- Patient either isn't a candidate for biopsy or owner not consenting
- Most likely diagnosis is immune-complex glomerulonephritis
- Infectious disease testing has all returned negative
 - Leptospirosis
 - Histoplasmosis
 - Heartworm
 - Vector-borne disease (PCR and serology to infectious disease lab)



Canine Hyperlipidemia

- Disturbance of lipid metabolism causing increase concentration of lipoprotein levels
 - Increased synthesis of lipids
 - Decreased degradation of lipids
- Hypertriglyceridemia/hypercholesterolemia
- Traditionally benign




Classification of Lipoproteins

- Chylomicrons
 - Largest and least dense
 - Derived from dietary fat and contain the highest [TG]
 - Associated with most common lipid disorders in animals
- VLDL
 - Mediates transfer of endogenous TG
- LDL
 - Mediates transfer of endogenous cholesterol
- HDL
 - Facilitates removal of excess cholesterol
 - Contains highest amount of cholesterol in animals



Triglycerides

- Ester derived from glycerol and three fatty acids
- Most abundant dietary lipid
- Uses
 - Source of stored energy in adipocytes
 - Cellular metabolism



Secondary/Acquired Hyperlipidemia

Common

- Hyperadrenocorticism (80%)
- Hypothyroidism (75%)
- Diabetes mellitus (50%)
- Pancreatitis (30%)
- Obesity (25%)
- Cholestasis
- Hepatic insufficiency
- Drugs
- Protein losing nephropathy*

Uncommon

- Lymphoma
- Parvoviral enteritis
- Leishmaniasis



Clinical Significance of Hyperlipidemia

- Influence on lab parameters
 - Can falsely increase bilirubin, TP, and phosphorus
 - Can falsely decrease creatinine, tCO₂, and chloride
 - Can interfere with ALP, albumin, and BG at very high levels
 - Can cause hemolysis
- Increased risk of disease
 - Pancreatitis
 - Hepatobiliary disease (VH, lipidosis, biliary mucocele)
 - Diabetes mellitus
 - Ocular disorders (blindness, lipid keratopathy, uveitis)
 - Dermatologic abnormalities (xanthomas)
 - CNS disturbances (seizures, mentation changes, peripheral neuropathies)




Clinical Signs of Hyperlipidemia

- Usually associated with the cause or effect of hyperlipidemia
- May include GI signs (V/D, hyporexia, abdominal discomfort)
- TG > 500mg/dL



Diagnostic Approach to Hyperlipidemia

1. Ensure proper fasting
2. Assess for drugs/risk
3. Look for underlying disease



Treatment Guidelines for Hyperlipidemia

- Indications for treatment
 - Hypertriglyceridemia >300mg/dL*
 - Hypercholesterolemia >500mg/dL
 - Presence of clinical signs or comorbidities
- Identify and treat underlying cause
- Principal treatments
 - Dietary modification/supplementation
 - Medical management



Dietary Management of Hyperlipidemia

- First line treatment
- Low fat diets with <25g total fat/1000kcal recommended
- Commercial vs. home-made diets
 - RC GI LF preferred by author
 - Home-made diets with turkey and rice
- Recheck lipid levels after 4-6 weeks then q6months if adequate response



Dietary Management of Hyperlipidemia

Received: 10 January 2020 | Accepted: 13 August 2020
DOI: 10.1111/jvim.15880

STANDARD ARTICLE

Journal of Veterinary Internal Medicine **ACVIM**
American College of Veterinary Internal Medicine

Effect of a low-fat diet on serum triglyceride and cholesterol concentrations and lipoprotein profiles in Miniature Schnauzers with hypertriglyceridemia

Panagiotis G. Xenoulis¹ | Paul J. Cammarata² | Rosemary L. Walzem³ |
Jan S. Suchodolski¹ | Jörg M. Steiner²



Conclusions

- Dogs (n=16) treated with RC GI LF for 8 & 12 weeks
- Serum cholesterol significantly reduced in all dogs
- Serum TG normalized in ~25% of dogs
- 15/16 dogs with TG >500 had levels fall <500

Dietary Supplements for Hyperlipidemia

• Chitosan

- Fiber supplement derived from shellfish
- Binds dietary TG decreasing absorption
- No studies proving efficacy
- No adverse effects
- Recommended dose: 250-500mg q12hr 30min before meals
- Not recommended to use Epakitin



Dietary Supplements for Hyperlipidemia

• Omega-3 Fatty Acids (DHA/EPA)

- Reduces lipogenesis of VLDL and LDL and increases lipoprotein lipase activity
- Masaki-Tovi et. al 2014 showed that 20 healthy dogs given 220mg/kg daily for 30d had significant reductions in [TG]
- Albuquerque et. al 2021 showed that MS given 730mg/d had a 36% and 20% reduction in [TG] and [CH] without a low fat diet
- Little to no adverse effects
- Recommended dose: 200-300mg/kg SID
- Take care to use high quality products



Medical Management of Hyperlipidemia

- Fibric acid derivatives
 - Increases fatty acid oxidation and lipoprotein lipase activity
 - Recommended when diet and omega-3 treatment fails
 - More effective at lowering triglyceride than cholesterol
 - Adverse effects: GI upset, hepatotoxicity, choleliths, myalgia/myopathy
 - Drugs: Fenofibrate*, Bezafibrate, Gemfibrozil
 - Recommended to recheck liver values and lipid levels after 30d




Fenofibrate for Hyperlipidemia

- Recommended starting dose: 6.5-10mg/kg
- Generic vs. nanocrystal formulation (Tricor®)
- Very effective and well tolerated

Received: 22 December 2020 | Accepted: 18 May 2021
DOI: 10.1111/jvim.15190

STANDARD ARTICLE

Journal of Veterinary Internal Medicine 


Domestic Animal Endocrinology
Volume 94, January 2021, 106178

Fenofibrate treatment for severe hypertriglyceridemia in dogs

Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs

Matthew J. L. Munro^{1,2} | Sean E. Hulsebosch³ | Stanley L. Marks² | Chen Gilor^{1,4}

D.D. Moxell^{1,5} | V.P. Vidal⁶ | M.F.C. Blamer⁷ | O.P. Pignataro⁸ | V.A. Castillo⁹



Medical Management of Hyperlipidemia

- Niacin
 - Acts primarily to reduce hepatic triglyceride synthesis
 - Studies lacking
 - Side effects: erythema, pruritus, restlessness, myotoxicity, hepatotoxicity
 - Use with caution in diabetic patients
 - Recommended dose: 50mg/d titrated up to 200-300mg/d




Medical Management of Hyperlipidemia

- HMG CoA-reductase inhibitors or “Statins”
 - Most powerful cholesterol reducing medications available
 - Have little effect on lowering triglyceride levels
 - Side effects: lethargy, diarrhea, myopathy, hepatotoxicity
 - Should not be used concurrently with fibrates
 - Recommended dose: Atorvastatin – 5mg/kg/d; Lovastatin 10-20mg/kg/d



Canine Hyperlipidemia “Vader”

- 8yr MN Miniature Schnauzer
- PPH: Atopic dermatitis
- Current hx
 - 5-7 days of lethargy and reduced appetite
 - RV labwork: ALT 158, ALP 1087, cholesterol 614
 - Referred for AUS and concern for pancreatitis and/or hyperadrenocorticism



Canine Hyperlipidemia “Vader”

- Physical Exam
 - BCS 7/9; normal vital parameters
 - Euhydrated
 - Normal thoracic auscultation; palpation hepatomegaly
- Diagnostics
 - CBC/Chemistry panel: ALT 162, ALP 1114, cholesterol 602, triglycerides 2356, wbc 18.4k, neutrophils 11k with mild left shift
 - Urinalysis: usg 1.029, 1+ protein; UPC 0.8
 - T4 1.4
 - Abdominal ultrasound: enlarged hyperechoic liver with few nodules, mild biliary sludge accumulation, moderately heterogenous pancreas with irregular margination mild surrounding peritonitis, normal adrenal glands
 - LDDS test: resting - 3.2, 4hr – 0.5, 8hr – 0.4



Canine Hyperlipidemia "Vader"

- Presumptive diagnosis: Pancreatitis associated with primary hyperlipidemia and suspected vacuolar hepatopathy
- Initial Treatment
 - Hospitalized for 3 days for pancreatitis
 - Discharged on clavamox, cerenia, and RC GI LF
- Follow-up @ 2 weeks
 - Much improved; eating 90%, no vomiting or diarrhea
 - Focused u/s noted resolution of peritonitis
 - Repeat bloodwork: ALT 202 (162), ALP 984 (1114), cholesterol 491 (602), triglycerides 1716 (2356)
 - Started omega-3 fatty acids and denamarin and continued RC GI LF




Canine Hyperlipidemia "Vader"

- Follow-up @ 6 weeks
 - Doing well at home; no issues
 - Repeat bloodwork: ALT 122 (202), ALP 1001 (984), cholesterol 449 (491), triglycerides 1262 (1716)
 - Added fenofibrate at 10mg/kg/d
- Follow-up @ 10 weeks
 - Still doing well at home
 - Repeat bloodwork: ALT 68 (122), ALP 532 (1001), cholesterol 216 (449), triglycerides 299 (1262)
 - Continued omega-3 FA, fenofibrate, and RC GI LF



Canine Hyperlipidemia

- Seen on a daily basis and often underestimated
- Hypertriglyceridemia most common lipid disorder in dogs and cats
- Pancreatitis is major complication
- Diagnosis requires a 12 hour fast
- Identify and treat potential underlying causes
- Tx: low fat diet, omega-3 fatty acids, fibrates



The end you have reached. Wiser
have you become



What are some guidelines for the management of megaesophagus?
 What is a good ¹³¹I candidate?
 Patient with a flare of IMT. How do I manage?
 How do I best manage a dog with collapsing airway disease?
 When do I need to be worried about increases in cholesterol/triglycerides?
 Is laser lithotripsy a viable option to remove bladder stones?
 What probiotic is best for dogs and cats?
 Patient with suspected hyperadrenocorticism but normal LDDS.
 What is next best step?
 When/how to manage proteinuria in a dog?
 Cat with suspected ureteral calculi. What are options for care?
 Can I get some information of the new pancreatitis drug available?
 How best to treat a case of histoplasma or heterobilharzia?
 Cat with suspected FIP. Are there any new treatments?
 How do I best incorporate the use of a wearable glucose monitor?





I recently saw a cat for some respiratory problems and radiographs of his chest were read out as concerning for fungal disease. I recommended seeing a specialist but the owner has financial limitations and so I was looking for some guidance on what we might be able to do?



Histoplasmosis

- Causative disease of *Histoplasma Capsulatum*
- Saprophytic, dimorphic fungus
 - Free-living mycelium in nature
 - Yeast in host tissue that reproduces by budding
 - 2-4µm with a thin, clear cell wall that surrounds a round or crescent-shaped basophilic cytoplasm
- Endemic within the Mississippi, Missouri, and Ohio River valleys



Source: Miravita Labs




Histoplasmosis – Risk Factors

- Young animals (<4yrs)
- Exposure to large numbers of infective conidia
- Cats equally infected as dogs
- Correlation with immunosuppressive conditions not identified



Histoplasmosis – Pathogenesis




Clinical Signs of Histoplasmosis in Dogs

- **Gastrointestinal**
 - Seen in 80% of clinically infected dogs
 - Weight loss and large bowel diarrhea with hematochezia
 - Vomiting is rare
- **Pulmonary**
 - Usually subclinical
 - Seen in around 17% of infected dogs
 - Dyspnea, tachypnea, coughing, abnormal lung sounds
- Ocular, dermatologic, orthopedic, cutaneous signs uncommon



Diagnosis of Histoplasmosis

- Cytology/Histology
 - Historical gold standard
 - Bone marrow, lung, or Inn aspirates in cats
 - GI biopsies, rectal scrapings, or aspirates of liver, spleen, or Inn in dogs
 - Bx: Granulomatous to pyogranulomatous inflammation



Diagnosis of Histoplasmosis

- Serology
 - Unreliable and not recommended
 - Many false positives and negatives
- Antigen testing
 - Detects galactomannan in cell wall of fungi
 - Best performed on urine or CSF
 - EIA from Miravista preferred with Se of 95% and Sp of 99% (Clark, JVM 2021)
 - Cross reactivity with blastomyces and others possible
 - Higher rate of false negatives with renal insufficiency and primary ocular disease
 - Can be used to monitor response to therapy



Treatment of Histoplasmosis

- Indicated in all clinical cases
- Standards of Care
 - Itraconazole or fluconazole +/- amphotericin B
 - Treat for minimum of three months and at least one month past resolution of clinical signs
 - Recheck liver values in one month and then q2-3 months
 - Recheck antigen level after 8-16 weeks then q2-3 months
 - Author's preferred treatment: Minimum of 16 weeks followed by two consecutive negative antigen tests taken 2-3 months apart
 - Recommended q3-4 months antigen tests for first year after stopping tx



Treatment of Histoplasmosis - Itraconazole

- Drug of choice for both dogs and cats in most cases
- Generic vs. branded vs. compounded
 - Higher rates of variable bioavailability with compounded versions
- Liquid vs. capsules
 - Liquid products containing cyclodextrin (Itrafungol and Sporonox) have higher bioavailability (30%) than similar branded capsules
 - Liquid itraconazole best given on an empty stomach
 - Capsular itraconazole best given with fatty meal
- Possible GI signs and hepatotoxicity
- Dose: 5-10mg/kg BID



Treatment of Histoplasmosis - Fluconazole

- May be better with ocular or CNS involvement
- Undergoes renal excretion so may be safer with hepatic insufficiency
- Direct comparisons lacking but anecdotal evidence suggests equally as effective as itraconazole
- Treatment likely to be needed longer but generally less expensive
 - Author uses fluconazole for a minimum of 6 months
- Dose: 5-10mg/kg BID



What are some guidelines for the management of megaesophagus?
What is a good I¹³¹ candidate?
Patient with a flare of IMT. How do I manage?
How do I best manage a dog with collapsing airway disease?
When do I need to be worried about increases in cholesterol/triglycerides?
Is laser lithotripsy a viable option to remove bladder stones?
What probiotic is best for dogs and cats?
Patient with suspected hyperadrenocorticism but normal LDDS.
What is next best step?
When/how to manage proteinuria in a dog?
Cat with suspected ureteral calculi. What are options for care?
Can I get some information of the new pancreatitis drug available?
How best to treat a case of histoplasma or heterobilharzia?
Cat with suspected FIP. Are there any new treatments?
How do I best incorporate the use of a wearable glucose monitor?



AVIAN & EXOTICS



SUSAN BALEY
DVM, DABVP

Dr. Susan Baley received her Bachelor's degree in animal science with an emphasis in poultry management from the California Polytechnic State University in San Luis Obispo. She continued her education with a Doctor of Veterinary Medicine degree from the University of Minnesota in 2018. Upon graduation, she completed an avian and exotic animal medicine internship at Gulf Coast Veterinary Specialists. Dr. Baley completed a residency in avian medicine at Stahl Exotic Animal Veterinary Services in Fairfax, Virginia in 2021 and is actively working towards becoming board certified in avian practice.

Dr. Baley enjoys working with all kinds of exotics, but has a special interest in poultry medicine, endoscopy, and soft tissue surgery of exotic animals. Outside of the hospital, Dr. Baley enjoys hiking, playing video games, traveling, crafting, and spending time with her family and friends.



SUSAN.BALEY@GCVS.COM
713-693-1111

What medication can I use?

Drug Groups and Specific Examples that May be Used in Poultry in the United States

Drug Group	Examples
Macrolides	Tylosin, erythromycin
Tetracyclines	Oxytetracycline, chlortetracycline, doxycycline (extra-label)
Lincosamides	Lincomycin, clindamycin (extra-label)
Sulfonamides	Trimethoprim sulfa (extra-label)
Aminoglycosides	Gentamycin, novobiocin, streptomycin
Penicillins	
Spectinomycin	
Novobiocin	
Bacitracin	

Note: Prior to use, seek specific guidance on egg and meat withdrawal times.



Biosecurity



- Avoid the spread of disease by practicing good biosecurity
- Wash hands before and after handling poultry
- Put control programs in place for pests
- Clean/disinfect equipment used for poultry and their care
- Check your flock daily and quarantine any sick birds
- Report sick birds



Reportable Diseases in Texas

Poultry diseases

- Avian influenza - Orthomyxoviruse
- Avian infectious laryngotracheitis - Orthomyxovirus, herpesvirus
- Avian tuberculosis - Mycobacterium avium serovars 1,2
- Duck virus hepatitis - Picornavirus
- Fowl typhoid - Salmonella gallinarum
- Highly pathogenic avian influenza (fowl plague) – Orthomyxovirus (type H5 or H7)
- Infectious encephalomyelitis - Arbovirus
- Ornithosis (psitticosis) - Chlamydia psittaci
- Pullorum disease - Salmonella pullorum
- Newcastle disease (VVND) - Paramyxovirus-1 (PMV-1)
- Paramyxovirus infections (other than Newcastle disease) - PMV-2 to PMV-9



Good resources for more information



- Texas Animal Health Commission
- <https://www.tahc.texas.gov/regs/reportable.html>
- Texas Department of State Health Services <https://www.dshs.texas.gov/> For zoonotic diseases



Physical Examination

- Start with a hands-off approach
 - Body posture, mentation
 - Respiratory rate/effort
- Eyes, nares, ears
- Head, neck, comb, wattles
- Oral cavity- tongue, choana, beak
- Feathers
- Coelomic palpation
- Auscultation- heart, lungs, air sacs
- Legs and feet
- Vent



Common Backyard Chicken Emergencies

Reasons for evaluation on an emergency basis of and short-term outcomes for chickens from backyard flocks: 78 cases (2014–2017)

OBJECTIVE
To investigate the reasons for evaluation on an emergency basis of and short-term outcomes for chickens from backyard flocks.

DESIGN
Retrospective case series.

ANIMALS
78 chickens.

PROCEDURES
The chickens evaluated on an emergency basis in a New England veterinary teaching hospital in January 2014 through March 2017, when owners including age, sex, and breed provided medical histories, full physical and ophthalmologic examinations, and laboratory testing. Primary medical problems were classified as trauma, respiratory tract disease, reproductive tract disease, and trauma.

RESULTS
78 chickens were evaluated on an emergency basis, of which 53 were females and 25 were males. The median age of the chickens was 1 year (range, 1 to 7 years). The most common problem was trauma (n = 33), followed by respiratory tract disease (n = 14) and reproductive tract disease (n = 14). The birds had respiratory tract disease, and 3 had abdominal masses. The birds were brought to the emergency service for evaluation and treatment, reproductive tract disease, and signs of illness. There were more frequent medical problems that were not life-threatening. The 78 (100%) chickens were given oral antibiotics.

CONCLUSIONS AND CLINICAL RELEVANCE
Backyard flocks are a common source of zoonotic disease and are an important source of information for zoonotic disease. Although approximately half of the backyard chickens were hospitalized, the remainder were discharged from the hospital and required medical management. (J Am Vet Assoc. 2018;223:1076–1080).

- Most common presentations ---- trauma followed by non-specific signs, and then reproductive disease.
- 50% of chickens that presented to ER service survived to discharge



Trauma



- Clean and irrigate open
- Bandage wounds to help stabilize the patient
- Analgesia- butorphanol, ketamine, tramadol
- Anti-inflammatory- meloxicam, carprofen
- If trauma is from a predator, start antibiotics ASAP
- Fracture stabilization follows the same principles as in other avian species
- Orthopedic surgery



RBG aka "Ruthie"

4 week old Easter egger

Attacked by a raccoon

Traumatic amputation of the left wing at the level of the humerus

Initial treatments

Analgesia – Butorphanol 2mg/kg IM

Meloxicam - 1mg/kg IM

Subcutaneous fluids- LRS 50ml/kg

Pip/Taz 100mg/kg IM



"Ruthie"



Continued treatments:

- Wound debridement under general anesthesia
- Sedation: butorphanol (2mg/kg) + midazolam (2mg/kg) + gas anesthesia
- Debrided edge of distal humerus and apposed muscle bellies over remaining bone of the humerus.
- Skin closed in a simple continuous pattern
- Discharged after 24 hours with meloxicam, clavamox, and gabapentin.



Reproductive Disease

- Common causes include: Egg binding, salpingitis, egg peritonitis, oviductal impaction or disease, ovarian/oviductal neoplasia
- Lethargy, dehydration, coelomic distension, increased resp. rate/effort, decreased egg production, abnormal eggs
- CBC/Chem panel, radiographs, U/S, cloacal endoscopy
- Tx: Antibiotics, anti-inflammatory medication, fluid therapy, +/- coelomocentesis
- Surgical exploratory and/or salpingohysterectomy



Oviductal or Cloacal Prolapse

- Stress, age, obesity, and poor nutrition can contribute
- Edematous, inflamed, necrotic
- Use moistened CTAs to return tissue to normal anatomic position
- Swelling can be reduced with lubrication, 50% dextrose, or sugar
- Important to find underlying cause of the prolapse, can often recur
- Salpingohysterectomy/Cloacoplasty may be needed



Respiratory Distress

- Potential causes: infectious disease, respiratory toxin, tracheal foreign body, severe esophageal trauma, organomegaly, ascites, neoplasia, cardiovascular disease
- Clinical signs:
 - Open beak breathing
 - Tail bobbing
 - Eyes closed
 - Hunched body position, keel sitting, or laying to the side
 - Pale or cyanotic or purplish comb/wattles



Respiratory Distress

- O2 cage/oxygen supplementation
- Injectable butorphanol 1-2mg/kg
- Midazolam 1-4mg/kg
- Treat underlying cause
- Blood work, radiographs, ultrasound
- Coelomocentesis may be needed if free fluid is noted on palpation



Respiratory Distress

- Place air sac cannula under gas anesthesia if indicated
- Obese chickens and poultry may have reduced air sac space



Respiratory disease

Mycoplasma gallisepticum

- Vertical and horizontal transmission
- Respiratory rales, ocular and nasal discharge, swelling of intraorbital sinuses with caseous pus, conjunctivitis, decreased egg production
- Diagnosis: PCR, serology, isolation
- Tx: Tylosin- treats the clinical signs, but does not eliminate the infection or carriers



Respiratory disease Avian Influenza

- Orthomyxovirus
- High pathogenicity **REPORTABLE**
- High morbidity/mortality
- Transmission- Direct and indirect
- Diagnosis: Virus isolation, PCR of choana or cloacal swabs
- Treatment: None. Depopulation is mandatory




Neurologic Disease

- Possible causes: Marek's, AI, Exotic Newcastle, AE, lead poisoning, trauma, nutritional deficiencies, ischemia, stroke, toxin.
- Clinical signs: Ataxia, torticollis, seizures, paresis, paralysis, weight loss, weakness, bright green feces with heavy metal toxicosis
- Treatment: Dependent on cause



Neurologic Disease Marek's Disease

- Gallid herpesvirus 2
- Mononuclear infiltration of nerves, organs, reproductive tract, iris, muscle and skin
- Cachexia, generalized weakness, diarrhea, pale comb, unilateral paresis/paralysis, iris color change to grey, swollen feather follicles
- No treatment
- Vaccine available- does not prevent contraction of the virus



NEUROLOGY




CARLEY GIOVANELLA DVM, DACVIM (NEUROLOGY)

Dr. Carley Giovannella received her doctor of veterinary medicine from Cummings School of Veterinary Medicine at Tufts University in 1999, followed by an internship at the University of Georgia. Her residency in neurology and neurosurgery was completed at the University of Wisconsin and the Animal Health Trust in Newmarket, England. Dr. Giovannella joined the faculty at The Ohio State University College of Veterinary Medicine in 2003 as an assistant professor and clinical neurologist/neurosurgeon. She became board certified by the American College of Veterinary Internal Medicine – Specialty of Neurology in 2004. She joined Gulf Coast Veterinary Specialists in 2005.



CARLEY.GIOVANELLA@GCVS.COM
713-693-1111

Disco in cats



Original Article
Imaging features of discospondylitis in cats

Sergio A Gómez¹, Sebastian Behr², Laurent S Garcia³, Inés Carreras⁴, Mike Targett⁵ and Mark Lourenço⁶

Sage Journals

J Feline Med Surg. 2022 Apr;34(4):311-321. doi: 10.1177/10986129211020159. Epub 2021 Jun 9.

Clinical features, treatment and outcome of discospondylitis in cats

Sergio A Gómez¹, Laurent S Garcia³, Sebastian Behr², Cristina Tora⁷, Joana Tabarnez⁴, Clare Ruttridge⁸, Mike Targett⁵, Mark Lourenço⁶


Affiliations
 PMID: 34700660 | DOI: 10.1177/10986129211020159

Abstract

Objectives: There is a paucity of information on feline discospondylitis. This study aimed to describe the signalment, clinical and laboratory findings, aetiological agents, treatment and outcome in cats affected by discospondylitis.

Clinical Signs - Location

- Pain
- Lethargy
- Fever
- Late:
 - Lameness
 - Severe pain
 - Nerve root signature
 - Incontinence




Organisms

- Staph pseudintermedius
- Staph aureus
- Strep
- E.coli
- Fungal (Aspergillus, Coccidioides, Actinomyces)
- *Brucella



Urine Collection

- Urine collection:
 - Sterile cystocenteses




Additional Tests

- Fungal screen
 - Culture, serology, urine
 - Travel history
 - Penicillium purpurgenium (IT)
 - Blasto/crypto in US regions
- Brucella*
 - Two tests



Advanced Imaging


- CT
 - Endplate erosion
 - Osteomyelitis
 - Fractures
 - Rapid acquisition and evaluation of whole spine



Future

- Test animals in shelter/rescues?
 - Funding
 - Protocol
 - Enforcement

Questions?



Gulf Coast Veterinary Specialists

Pathology

- Routes through digestive and respiratory mucosa
- Poor inflammatory stimulus in the host
- B canis mostly abortive in animals (febrile in humans)
- Metritis, placentitis/abortion chorionic villi necrosis and bacteria
- Aborted fetus may have bronchopneumonia, myocarditis, renal hemorrhage, lymphadenitis and hepatitis.



Gulf Coast Veterinary Specialists

CRITICAL CARE



HERNAN BRACHO

DVM, MVZ, ESP

Dr. Bracho, originally from Mexico, earned his veterinary degree there. After a two-year Internal Medicine and Surgery residency, he practiced in Mexico City for 8 years. During his time at the Veterinary Teaching Hospital, he supervised Social Services and Practice Programs while also serving as an associate veterinarian.

In 2010, he moved to Houston, TX, practicing as a general practitioner and a key referring DVM for 6 years. Dr. Bracho even held the role of Chief of Staff at Banfield Pet Hospital. His desire for advanced training led him to pursue a three-year Emergency and Critical Care residency at the University of Wisconsin, culminating in July 2021.

With special interests in point-of-care ultrasound, cardiology, sepsis, and mentoring new veterinarians, Dr. Bracho is dedicated to medical excellence. Beyond his professional pursuits, he finds joy in soccer, fitness, photography, and travel. He shares his life with two rescue dogs, Nemi and Chip, who keep him active.



HERNAN.ANGULO-BRACHO@GCVS.COM


713-693-1111

Sepsis won't hesitate, will you?



Outline

- ▶ Definitions
- ▶ Current statistics
- ▶ Criteria for SIRS & sepsis
- ▶ Pathophysiology & key factors for SIRS/sepsis
- ▶ Treatment: bundle concept
 - ▶ Lactate
 - ▶ Source identification & control
 - ▶ Antibacterial therapy
 - ▶ Fluid/vasopressor/inotropic therapies



Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations

Carolin Fleischmann ^{1,2}, André Scherag ³, Neill K. J. Adhikari ⁴, Christiane S. Hartog ^{1,2}, Thomas Tsaganos ⁵, Peter Schlattmann ⁶, Derek C. Angus ^{2*}, and Konrad Reinhart ^{1,2*}; on behalf of the International Forum of Acute Care Trialists

* Author Affiliations

55,787 1,807

<https://doi.org/10.1164/rccm.201504-0781OC> PubMed: 26414292

Received: April 20, 2015 Accepted: September 25, 2015

Global estimates

- 31.5 million sepsis
- 19.4 million severe sepsis
- Potentially 5.3 million deaths/year

Statistics...

4

- ▶ 783 articles assessed
- ▶ 170 studies included
- ▶ Septic shock mortality
 - ▶ ~ 30-d 34.7% (33.7% in NA)
 - ▶ 90-d 38.5%
- ▶ Sepsis mortality
 - ▶ 30-d 24.4%
 - ▶ 90-d 32.2%

Research | [Open Access](#) | Published: 19 May 2020
Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019—results from a systematic review and meta-analysis
Michael Bauer , Herwig Gerlach, Tobias Vogelmann, Franziska Preissino, Julia Stiefel & Daniel Adam
[Critical Care](#) 24, Article number: 239 (2020) | [Cite this article](#)

Despite some evidence of lower mortality rates over the past decade, continuous reduction was not observed



Vetmed statistics...

5



Neonatal sepsis in dogs: Incidence, clinical aspects and mortality

[Keylla Helena Nobre Pacifico Pereira](#)¹, [Kárita da Mata Fuxos](#)², [Viviane Yukari Hibaru](#)³, [Luiz Eduardo Cruz dos Santos Correia](#)⁴, [João Carlos Pinheiro Ferreira](#)⁵, [Fabiana Ferreira de Souza](#)⁶, [Luiz Henrique de Araújo Machado](#)⁷, [Simone Biagio Chiacchio](#)⁸, [Maria Lucia Gomes Lourenço](#)⁹ 

RETROSPECTIVE STUDY | [Open Access](#)
Retrospective evaluation of the prognostic utility of quick sequential organ failure assessment scores in dogs with surgically treated sepsis (2011-2018): 204 cases
Yessica Bastany DVM , Arny M. Hoangpho DVM, DACVECC, Glenn E. Shadle DVM, Elton K. Chan DVM, Natalia A. Lima DVM, DACVECC
First published: 21 August 2021 | <https://doi.org/10.1111/avac.12191> | [Citation: 2](#)

Association between outcome and organ system dysfunction in dogs with sepsis: 114 cases (2003-2007)
[Dora de Moraes](#) DVM, [Elizabeth A. Frazee](#) DVM, [Dorcas Sanchez-Jacob](#) DVM, [Paula](#) DVM, [MELBAVIC](#) 
DOI: <https://doi.org/10.2460/javma.126.1.13>
Volume/Issue: Volume 126, Issue 1 | Online Publication Date: 01 Jan 2019



RETROSPECTIVE STUDY | [Open Access](#)
Retrospective evaluation of the use of quick Sepsis-related Organ Failure Assessment (SOFA) as predictor of mortality and length of hospitalization in dogs with pyometra (2013-2018): 52 cases
Fátima Torres DVM, MS, [Lorena A. Lucchetti DVM, DACVIM](#) , [Marcelo Torres DVM, César Vilalba DVM, Rafael C. Guedes DVM, PhD](#)


Research article | [Open Access](#) | Published: 20 June 2020
Canine parvovirus: a predicting canine model for sepsis
[L. Rossi](#), [L. Puga](#), [L. Nunes](#), [J. Gomes](#), [S. Araújo](#), [L. Lima da Silva](#), [L. Soares](#), [V. Almeida](#) [PLoS ONE](#) 15(6): e0121111, 2020
[BMC Infectious Diseases](#) 19, Article number: 949 (2019) | [Cite this article](#)

6



Statistical conclusions in vetmed

- ▶ Incidence is unknown
- ▶ Mortality **appear** to be high, (20 to 70% **or more**)




8

Definitions

- ▶ **Bacteremia**
 - ▶ Live bacteria in the bloodstream

- ▶ **Systemic inflammatory response syndrome (SIRS)**
 - ▶ Exaggerated inflammatory response to stressors




► Sepsis

Life threatening organ dysfunction caused by a dysregulated host response to infection

► Septic shock (SS)

► Sepsis + circulatory failure





11

Where to start?

Gulf Coast Veterinary Specialists

SIRS criteria

1. Hypo or hyperthermia
2. Leukocytosis or leukopenia
 1. Bands %
3. Tachycardia/ Bradycardia C
4. Tachypnea

Table 6-1 Proposed Criteria for the Diagnosis of SIRS in Dogs and Cats

	Dogs (2/4 Changes Required)*	Cats (3/4 Changes Required)
Temperature (°C)	<100.6 or >102.6	<100 or > 104
HR (beats/min)	>120	<140 or >225
RR (breaths/min)	>20	>40
WBC ($\times 10^3/\mu\text{l}$); % bands	<6 or >16; >3%	>19 or <5

HR, Heart rate; RR, respiratory rate; SIRS, Systemic inflammatory response syndrome; WBC, white blood cells.


*Proposed criteria for the diagnosis of SIRS include at least two (in dogs) or three (in cats) of the changes listed. Criteria described for dogs were found to have a sensitivity of 97% and a specificity of 64% for the diagnosis of SIRS.²⁶

Gulf Coast Veterinary Specialists

Common septic foci in D&C

16

SITE	DOG	CAT
Respiratory/pleural	20%	24%
Peritoneal cavity	35%	47%
Gastrointestinal	4%	5%
Reproductive	25%	
Urinary	4-10%	7-8%
Soft tissue	29%	16%
Cardiovascular		14%




GIC VIS GULF COAST VETERINARY SPECIALISTS

Is my patient septic?

17

- ▶ SIRS criteria (1 suspicion)
- ▶ Laboratory findings
 - ▶ WBC abnormalities
 - ▶ Bands!! >2%
 - ▶ Toxic Neu
 - ▶ Thrombocytopenia
 - ▶ Coagulopathies



Source: Lichtman MA, Shafer MS, Felgar RE, Wang N; Lichtman's Atlas of Hematology; <http://www.accessmedicine.com>; Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Confirmation (or high suspicion) of a septic foci

GIC VIS GULF COAST VETERINARY SPECIALISTS

Is my patient in septic shock?

18



Meets sepsis criteria AND...

- ▶ Hyperlactatemia >2 mmol/L
- ▶ Hypotension
 - ▶ MAP < 60-65 mm Hg
 - ▶ Doppler BP < 90 mmHg
- ▶ Dysglycemia?


GIC VIS GULF COAST VETERINARY SPECIALISTS

SIRS-sepsis Pathophysiology



SIRS-sepsis pathophysiology

- 1. Infectious or non-infectious insult
- 2. Expression of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs)
- 3. Stimulation of pathogen recognition receptors (PRRs), toll-like receptors (TLRs) or other systems in immune host cells



Pathophysiology

- 5. Proinflammatory mediators circulate & cause:
 - 1. peripheral vascular dilation, increased capillary permeability, & depressed cardiac function

3 forms of shock occur simultaneously
- 6. Shock \rightarrow MODS \rightarrow death




Figure 1.3 A schematic depicting the presence of proinflammatory (blue) and antiinflammatory (yellow) mediators released concurrently (green), causing hemodynamic changes that result in three simultaneous forms of shock.



Bundle elements

1. Lactate
2. Source identification (blood , tissue & fluid cultures)
3. Early source control & antimicrobial administration
4. Septic shock treatment (fluids, vasopressors)

Lactate

- ▶ Bioproduct of anaerobic metabolism
 - ▶ Hypoperfusion
 - ▶ **I** catecholamines
 - ▶ Underlying disease
- ▶ Measure within 1st hour of admission
- ▶ Recheck 2-4 h after volume resuscitation
- ▶ Continue resuscitation until normal



Bundle elements

1. Lactate
2. Source identification (blood , tissue & fluid cultures)
3. Early source control & antimicrobial administration
4. Septic shock treatment (fluids, vasopressors)



Source identification

- ▶ Blood cultures: standard of care in humans (30-50% positive)
 - ▶ vetmed < 49%
- ▶ Promotes antibacterial selection (DEESCALATION!)
- ▶ Sampling **MUST** not delay tx

29

Table 2. Species of bacteria isolated from the blood of 140 dogs and 39 cats with positive blood cultures

Bacterial isolates	Gram stain	Dogs	Cats
<i>Staphylococcus</i> species	+	26/4% (n=42)	2/5% (n=1)
<i>Streptococcus</i> species	+	13/8% (n=22)	7/5% (n=3)
<i>Enterococcus</i> species	+	5/7% (n=9)	5/0% (n=2)
<i>Moraxella</i> spp	-	0/0% (n=1)	0/0% (n=0)
<i>Escherichia coli</i>	-	29/4% (n=47)	30/0% (n=12)
<i>Pasteurella</i> species	-	4/4% (n=7)	5/0% (n=2)
<i>Enterobacter</i> species	-	3/8% (n=6)	15/0% (n=6)
<i>Pseudomonas</i> species	-	2/5% (n=4)	7/5% (n=3)
<i>Mycobacterium</i> species	-	2/5% (n=4)	2/5% (n=1)
<i>Serratia marcescens</i>	-	1/3% (n=2)	0/0% (n=0)
<i>Campylobacter jejuni</i>	-	0/0% (n=1)	0/0% (n=0)
<i>Salmonella</i> species	-	0/0% (n=0)	7/5% (n=3)
<i>Yersinia pseudotuberculosis</i>	-	0/0% (n=0)	2/5% (n=1)
Anaerobic bacteria	n or -	8/8% (n=14)	15/0% (n=6)



A retrospective study of the clinical presentation of 140 dogs and 39 cats with bacteraemia

M. Green, G. Wolf, N. Hartmann
First published: 28 July 2016 | <https://doi.org/10.1111/j.1365-3113.2016.05646.x> | Evidence 39

Bundle elements

1. Lactate
2. Source identification (blood, tissue & fluid cultures)
3. Early source control & antimicrobial administration
4. Septic shock treatment (fluids, vasopressors)

Early source control

Early source control



- ▶ Mostly surgical
 - ▶ Infectious peritonitis
 - ▶ Pyometra
 - ▶ Bite wounds
 - ▶ Pyothorax
 - ▶ Necrotizing fasciitis

© 2005
LIFE SCIENCE
EXCELLENCE

Antibacterial administration



Recommendations SS21

- ▶ Low likelihood, defer antibacterials, keep looking
- ▶ Possible sepsis, no shock
 - ▶ 3h window
- ▶ High likelihood or septic shock
 - ▶ Within 1 hr





Antimicrobial approach

Sepsis/septic shock	Antibacterial coverage
"Simple"	Broad spectrum, gram neg
Risk MDR+sepsis/septic shock	Double gram neg
Risk MRSA+sepsis/septic shock	MRSA
Fungal	Antifungal
Virus	□□



- "Simple" sepsis
- ▶ Ampicillin/sulbactam
 - ▶ Ampicillin/enrofloxacin
 - ▶ 2nd/3rd cephalosporin
 - ▶ Trimetoprim/sulfas





MDR

- ▶ Ampicillin/sulbactam +
- ▶ Enrofloxacin
- ▶ Ceftazidime
- ▶ Amikacin
- ▶ TMS
- ▶ Piperacillin/tazobactam



MRSA

- ▶ Carbapenem
- ▶ Amikacin/Vancomycin
- ▶ Chloramphenicol
- ▶ TMS

Optimization of β -lactams




FIG. 177.2 Idealized example of the effect of standard, prolonged, or constant rate infusion (including a loading dose) of a β -lactam antimicrobial on the concentration in serum over time. The minimum inhibitory concentration of the example bacteria is 2 mg/ml and is represented by the dashed line. Source: Credit: Chrauda Tsoupekis Skouratakis, PhD.

- ▶ β -lactams can be used for all septic groups, except MRSA
- ▶ Time-dependent
- ▶ Standard infusion, extended infusion or CRI
- ▶ CONS:
 - ▶ Technically challenging vetmed
 - ▶ Augmented renal clearance
 - ▶ Lack of studies

Bundle elements

1. Lactate
2. Source identification (blood , tissue & fluid cultures)
3. Early source control & antimicrobial administration
4. Septic shock treatment (fluids, vasopressors)

Fluid therapy

- ▶ 3 shock types, only **ONE** responds to fluid therapy



41




Figure 1.3 A schematic depicting the presence of proinflammatory (blue) and anti-inflammatory (yellow) mediators released concurrently (green), causing hemodynamic changes that result in three simultaneous forms of shock.

Initial recommendations

42

1. Bolus (at least) 30 ml/kg balanced crystalloids in first 3h- SS21
 - ▶ 10-20 "rule"
 - ▶ 10-20 ml/kg over 10-20 min
2. Calculate deficit + maintenance & administer
3. Fluid responsiveness assessment
4. Bolus #2
 - 2. Start 🐶 🐱 🐭 🐹




Is there evidence of vasodilatory or cardiogenic shock?

Vasopressor therapy

43

- ▶ Early use improves outcome
- ▶ Norepinephrine (NE) 1st, Vasopressin (AVP) 2nd
- ▶ NE starting dose depends on SS severity
 - ▶ Early, NE 0.05 mcg/kg/min
 - ▶ High suspicion, non-critical 0.1 mcg/kg/min
 - ▶ Severe SS 0.3-0.5 mcg/kg/min
- ▶ Max dose: 1 mcg/kg/min, then add 2nd



Vasopressor therapy

44



- ▶ Higher dose have multiple detrimental effects
 - ▶ myocardial O₂ demand
 - ▶ CO
 - ▶ regional blood flow
 - ▶ Renal!!!
 - ▶ Immunosuppression

Vasopressor therapy

45

Arginine Vasopressin (ADH)

- ▶ Vasopressin (AVP) 1-4 mU/kg/min
- ▶ AVP is degraded/depleted during sepsis/ss
- ▶ Faster SS resolution vs monotherapy
- ▶ Reduced catecholamine dose, & easier wean-off



Dobutamine

46

Why?

Septic cardiomyopathy

- ▶ Cytokines
- ▶ LPS
- ▶ NO
- ▶ Complement
- ▶ Synthetic dopamine analog
- ▶ Increase forward cardiac flow




Figure 1.3 A schematic depicting the presence of proinflammatory (blue) and antiinflammatory (yellow) mediators released concurrently (green), causing hemodynamic changes that result in three simultaneous forms of shock.



Key points

47

- ▶ Sepsis/SS: high morbidity/mortality
- ▶ Sepsis can be challenging to diagnose
- ▶ Act early, don't wait
- ▶ Antibacterial selection is important
- ▶ There are 2-3 shock types, not all is solved with IV crystalloids
- ▶ Septic/SS patients requires ICU specialized care
- ▶ Initial interventions can be life saving





48

Thank you!



- Sepsis main cause of neonatal death in 1st 3wk age
- Mortality rate 25.6%
 - Early mortality (0–2 d) 69%
- Morbidity & mortality of neonatal septic dogs are high

- 78% dogs had 1+ dysfunctional organ systems
- 50% dogs had MODS
- Mortality increased w/ number of dysfunctional organ systems
- Mortality 70% for dogs in MODS, 25% without.

SURGERY



KRISTIN COLEMAN **DVM, MS, DACVS**

Dr. Coleman graduated from Auburn University in 2008, earning her Bachelor of Science degree in Microbiology with the Biomedical Sciences Dean's Medal. Remaining in the Southeast, she continued her education and received her Doctor of Veterinary Medicine degree from Auburn University in 2012, earning the Small Animal Surgery proficiency award.

Afterward, she completed a general rotating medicine and surgery internship at the Animal Medical Center in Manhattan in 2013. This was followed by a combined Small Animal Surgery residency and Master of Science degree at Colorado State University Veterinary Teaching Hospital in Fort Collins, Colorado.


In 2016, Dr. Coleman embarked on her career journey by joining a bustling private practice in Brooklyn, New York, and within months, achieved board certification from the American College of Veterinary Surgeons.



KRISTIN.COLEMAN@GCVS.COM
713-693-1111

**SURGICAL TREATMENT OF
BRACHYCEPHALIC OBSTRUCTIVE
AIRWAY SYNDROME**

KRISTIN COLEMAN, DVM, MS, DACVS
GULF COAST VETERINARY SPECIALISTS (GCVS), HOUSTON, TX
GCVS SYMPOSIUM – AUGUST 2023



1

CONFLICT OF INTEREST DISCLOSURE

I HAVE NO RELEVANT FINANCIAL INTEREST, ARRANGEMENT OR
AFFILIATION WITH ANY COMPANY OR ORGANIZATION.

2

GOAL OF TODAY

- BECOME COMFORTABLE WITH BOAS ANATOMY AND WHAT CAN BE DONE TO HELP THESE ANIMALS BREATHE
- EITHER BECOME COMFORTABLE WITH POSSIBLY PERFORMING THESE PROCEDURES OR DISCUSSING WITH CLIENTS BEFORE REFERRING



4

BOAS

- ENGLISH BULLDOG
- FRENCH BULLDOG
- PUG
- BOSTON TERRIER
- (SOME) SHIH TZU
- (SOME) CAVALIER KING CHARLES SPANIEL

- CLINICAL SIGNS
- UPPER AIRWAY OBSTRUCTION
- EXERCISE INTOLERANCE
- COLLAPSE
- CYANOSIS
- +/- GASTRO-ESOPHAGEAL REFLUX
- +/- SLIDING HIATAL HERNIA

5

OUTLINE

- ANATOMY OF THE AIRWAY
PRIMARY & SECONDARY COMPONENTS
- PATHOPHYSIOLOGY
COMPONENTS OF BOAS
- SURGICAL INTERVENTION OF SOME COMPONENTS
- PRE- & POST-OP CONSIDERATIONS
- WHEN TO TRACH & OPTIONS



6

ANATOMY OF THE AIRWAY

- CONCHAL GROWTH
- NASOPHARYNGEAL COMPRESSION
- ABERRANT NASAL TURBINATES
- SOFT PALATE HYPERPLASIA
- MACROGLOSSIA




- PRIMARY COMPONENTS:
- STENOTIC NARES, ELONGATED SOFT PALATE, HYPOPLASTIC TRACHEA
- SECONDARY COMPONENTS:
- EVERTED LARYNGEAL SACCULES OR TONSILS, TONSILLAR ENLARGEMENT, LARYNGEAL COLLAPSE AND EDEMA

7

PATHOPHYSIOLOGY OF BOAS

MARES CAN COLLAPSE ON INSPIRATION

- ELONGATED SOFT PALATE CAN PROTRUDE INTO THE RIMA GLOTTIS
- INTERFERES WITH LAMINATE AIRFLOW
- REDUCED AIRWAY DIAMETER
- INCREASED UPPER AIRWAY RESISTANCE
- GREATER NEGATIVE INTRATHORACIC PRESSURE TO COMPENSATE FOR ADEQUATE FLOW





8

PATHOPHYSIOLOGY OF BOAS

INCREASED WORK OF BREATHING WITH DYNAMIC PRESSURE CHANGE

- FURTHER EXACERBATION OF COLLAPSIBLE AIRWAY PASSAGES
- FURTHER INCREASE IN AIRWAY RESISTANCE
- CAN LEAD TO INFLAMMATION AND EDEMA OF THE PHARYNGEAL TISSUES

9


COMPONENTS OF BOAS

- HYPOPLASTIC TRACHEA
- STENOTIC NARES
- ELONGATED SOFT PALATE
- EVERTED LARYNGEAL SACCULES
- REDUNDANT NASOPHARYNGEAL TURBINATES / ABNORMAL CONCHAE
- ENLARGED TONGUE BASE
- EVERTED OR ENLARGED
- TONSILS LARYNGEAL COLLAPSE

10

PRE-OPERATIVE EVALUATION


- ENSURE OWNERS ARE INFORMED OF RISKS ASSOCIATED WITH BOAS SURGERY:
 - TEMPORARY TRACHEOSTOMY TUBE
 - ASPIRATION PNEUMONIA
 - CONTINUED GI SIGNS



11

PRE-OPERATIVE EVALUATION

- PRE-OPERATIVE DIAGNOSTIC TESTS
- PHYSICAL EXAMINATION
- THORACIC RADIOGRAPHS
- PNEUMONIA? HIATAL HERNIA? NCPE?
- TRACHEAL SIZE
- BLOODWORK
- +/- VIDEOFLUOROSCOPIC CONTRAST SWALLOW STUDY
- +/- HEAD CT SCAN



Journal of Veterinary Internal Medicine

Prevalence of esophageal imaging features in brachycephalic versus non-brachycephalic dogs based on videofluoroscopic swallowing studies

Caroline Dees, Rocio Chicon-Ruiz, Tereza Lutz, Silke Seiwald-Schmitt

First published: 19 June 2019 | https://doi.org/10.1111/jvim.15047 | Citations: 1


12

PRE-OPERATIVE CONSIDERATIONS

- 97% OF BOAS DOGS HAVE GI LESIONS
- ENDOSCOPY + BIOPSIES OF STOMACH & DUODENUM
- SOME DO NOT EVEN HAVE CLINICAL SIGNS OF GI ISSUES!
- 80% OF DOGS HAD IMPROVEMENT IN GI SIGNS POST-OP

SEVERITY OF AIRWAY DISEASE CORRELATED WITH SEVERITY OF DIGESTIVE SIGNS

• SIGNIFICANT IN FRENCHIES, MALES, AND HEAVY DOGS



JSAP BSAVA

Prevalence of gastrointestinal tract lesions in 73 brachycephalic dogs with upper respiratory syndrome

C. M. Pothol, G. P. Dupuis, V. G. Pralho, M. M. Estrada, T. A. Pothol, S. M. Boney

First published: 01 June 2020 | https://doi.org/10.1111/jvim.15677 | Citations: 129

PANTOPRAZOLE

METOCLOPRAMIDE

13

PRE-ANESTHETIC PLANNING

RISK OF ANESTHESIA-RELATED COMPLICATIONS IN BRACHYCEPHALIC BREEDS
JAVMA 2018 - GRUENHEID M, AARNES TK, MCLOUGHLIN MA, ET AL.

- AROUND 50% PERI-ANESTHETIC COMPLICATIONS FOR BOTH GROUPS
- POST-ANESTHETIC COMPLICATIONS: 8.7% BAS, 3.6% NON-BAS
- 1.57X MORE LIKELY TO EXPERIENCE AN INTRAOPERATIVE COMPLICATION
 - RISK INCREASED WITH EVERY 30 MINUTE INCREASE OF ISOFLURANE ANESTHESIA
- 4.33X MORE LIKELY TO HAVE A POST-OPERATIVE COMPLICATION
 - RISK INCREASED WITH EACH 30 MINUTE INCREASE OF ISOFLURANE ANESTHESIA

14

PRE-ANESTHETIC PLANNING

RISK OF ANESTHESIA-RELATED COMPLICATIONS IN BRACHYCEPHALIC BREEDS

- ORTHOPEDIC CASES APPEARED SAFER COMPARED TO SOFT TISSUE CASES
- INVASIVE PROCEDURE WERE 5X AS LIKELY TO CAUSE POST-OP COMPLICATIONS VS NON-INVASIVE
- MOST COMMON POST-OP COMPLICATION WAS ASPIRATION PNEUMONIA
- KETAMINE AND BENZODIAZEPINE LEAD TO MORE POST-ANESTHETIC COMPLICATIONS THAN IF JUST PROPOFOL WAS USED



15

PRE-ANESTHETIC PLANNING

ANESTHETIC RISK DURING SUBSEQUENT ANESTHETIC EVENTS IN BRACHYCEPHALIC DOGS THAT HAVE UNDERGONE CORRECTIVE AIRWAY SURGERY: 45 CASES (2007-2019)


JAVMA 2020
DOYLE CR, AARNES TK, BALLASH GA, ET AL.

- ODDS OF COMPLICATIONS DURING POST-ANESTHETIC PERIOD FOLLOWING SUBSEQUENT ANESTHETIC EVENTS DECREASED BY 79% IN DOGS THAT HAD PREVIOUS AIRWAY SX
- INTRA-ANESTHETIC BRADYCARDIA INCREASED ODDS OF DEVELOPING POST-ANESTHETIC COMPLICATION BY 4.5X
- EVERY 15-MINUTE INCREASE IN ANESTHETIC DURATION INCREASED ODDS OF POST-ANESTHETIC COMPLICATION BY 12% & INTRA-ANESTHETIC COMPLICATION BY 11%

16

PRE-ANESTHETIC PLANNING

- PREOXYGENATION
 - INCREASE OXYGEN STORES VIA FUNCTIONAL RESIDUAL CAPACITY
- RAPID INTUBATION
- RAPID SMOOTH RECOVERY à AVOID LONG-ACTING DRUGS
- USE INHALANTS WITH FASTER RECOVERY TIME
 - SEVOFLURANE AND DESFLURANE
- REMEMBER ALL INHALANTS PRODUCE A DOSE-DEPENDENT REDUCTION OF ßINOTROPY, SYSTEMIC VASCULAR RESISTANCE, AND PRE-LOAD



17

PRE-OPERATIVE PREPARATION


- NO FOOD FOR 24 HRS PRIOR TO SURGERY
- LIGHT PLANE OF ANESTHESIA + FLOW-BY O2
 - 0.3 MG/KG METOCLOPRAMIDE SC
 - 1 MG/KG PANTOPRAZOLE
 - 1 MG/KG MAROPITANT
- PROPOFOL TO EFFECT
- SEDATED OROPHARYNGEAL / LARYNGEAL EXAMS
- DOXAPRAM 1 MG/KG IV BOLUS



18

LARYNGEAL EXAM

- SOFT PALATE LENGTH &
- THICKNESS SACCULES & TONSILS
- LARYNGEAL COLLAPSE
- LARYNGEAL FUNCTION
- NASOPHARYNX
- TONGUE
- OTHER MASSES OR LESIONS



19



Oral Prep (0.12% Chlorhexidine Diacetate)
 (Modified after CET Oral Hygiene Rinse)
 940 mls Tap Water & 60 mls of Nolvasan

20

COMPONENTS OF BOAS

- HYPOPLASTIC TRACHEA
- STENOTIC NARES
- ELONGATED SOFT PALATE
- EVERTED LARYNGEAL SACCULES
- REDUNDANT NASOPHARYNGEAL TURBINATES / ABNORMAL CONCHAE
- ENLARGED TONGUE BASE
- EVERTED OR ENLARGED TONSILS
- LARYNGEAL COLLAPSE

22


- Hypoplastic Ratio <0.16
- Normal trachea Ratio >0.20
- Most common dog breed to experience this: English Bulldog



23

SURGERY: STENOTIC NARES



- TRADER'S TECHNIQUE
- PUNCH TECHNIQUE
- AL APEXY
- VERTICAL ALAR WEDGE RESECTION
- HORIZONTAL WEDGE RESECTION



24

TRADER'S TECHNIQUE

- ORIGINALLY REPORTED IN SHIH TZU PUPPIES
- NEED PRESSURE OR TOPICAL EPINEPHRINE TO CONTROL BLEEDING



25

TRADER'S TECHNIQUE

- #11 BLADE POINTED VENTROLATERALLY
- AMPUTATE VENTRAL ALAR WING
- APPLY PRESSURE WITH DRY GAUZE STRIP
- REPLACE WITH GAUZE STRIP SOAKED IN DILUTE EPINEPHRINE
- TRIM ADDITIONAL TISSUE FOR SYMMETRY



26

PUNCH TECHNIQUE


- 2MM – 6MM PUNCH
- GRASP PLUG OF TISSUE WITH FORCEPS
- EXCISE BASE WITH METZENBAUM SCISSORS
- GOAL IS TO LEAVE 2-3MM RIM OF TISSUE FOR SUTURING



27

ALAPEXY

- TWO SMALL ELLIPTICAL INCISIONS
- ABDUCT ALAE
- MAY BE MORE DIFFICULT THAN OTHER WEDGE RESECTIONS
- OPTION IF OTHER TECHNIQUES HAVE FAILED



28


VERTICAL ALAR WEDGE RESECTION

- OTHER OPTION: HORIZONTAL WEDGE
- MAKE SURE INCISION IS DEEP TO LEVEL OF NASAL CONCHA
- FIRST SUTURE APPoses ROSTROVENTRAL MARGIN



Tobias, Manual of Soft Tissue Surgery

29




WHAT CAN GO WRONG?

- INFECTION!
- HINT: DON'T USE CATGUT SUTURE ON THE NARES.

30


VERTICAL ALAR WEDGE RESECTION



31

VERTICAL ALAR WEDGE RESECTION

- LEAVING A TAG AND HOLDING YOUR FIRST SUTURE DORSALLY AS STAY SUTURE ALLOWS INTRA-NASAL SUTURING
- +/- TOPICAL EPINEPHRINE ON COTTON-TIPPED APPLICATOR FOR HEMORRHAGE
- 0.1ML DILUTED 1:1 WITH SALINE AND DIVIDED ON 2 Q-TIPS FOR BOTH NOSTRILS



32

ALAR FOLD VESTIBULOPLASTY / MODIFIED TRADER'S TECHNIQUE

- FIRMLY GRASP ALAR FOLD WITH A CURVED HEMOSTAT, #11 BLADE USED TO SHARPLY INCISE AT BASE TO RESECT
- MODIFIED TRADER'S IS PERFORMED TO EXCISE DORSAL WALL OF ALAR FOLD TO LEVEL OF NASAL VESTIBULE
- HEMOSTASIS VIA PRESSURE WITH CTA + PHENYLEPHRINE-SOAKED SPONGES


33



Courtesy of Dr. Sarah Marvel

VERTICAL WEDGE RESECTION IN A CAT


34



35

SURGERY: ELONGATED SOFT PALATE

- "STAPHYLECTOMY"
- SOFT PALATE EXTENDS PAST CAUDAL ASPECT OF TONSILS
- MAY ALSO BE ABNORMALLY THICK
- EVIDENCE THAT SOFT PALATE MAY HAVE DENERVATION IN DOGS WITH BOAS



Tobias, Manual of soft tissue surgery

36

STAPHYLECTOMY: OPTIONS


- CUT-AND-SEW
- *MY FAVORITE*
- LASER
- BIPOLAR ELECTROSURGERY
- LIGASURE™
- FOLDED FLAP PALATOPLASTY
- *GREAT FOR THOSE MEATY PALATES*



37

STAPHYLECTOMY


- STERNAL RECUMBENCY
- ENSURE STRAIGHTNESS
- ELEVATE HEAD
- BE MINDFUL OF THEIR NECK!
- TIE ET TUBE TO MANDIBLE
- HEAD LAMP



38

STAPHYLECTOMY

- PLACE STAY SUTURES AT PLANNED RESECTION SITE
- ALWAYS VISUALIZE ORAL AND NASOPHARYNGEAL MUCOSA
- TAPING TONGUE OUT OF MOUTH AND DOWN OR USE MALLEABLE RETRACTOR



39

STAPHYLECTOMY


- ONLY CUT 50% OF SOFT PALATE AT A TIME
- OR, CUT IT ALL AT ONCE!

DISTANCE TO CUT:

- NO MORE CRANIAL THAN 1/3 – 50% OF LENGTH OF TONSILLAR CRYPT
- ALWAYS VISUALIZE ORAL AND NASOPHARYNGEAL MUCOSA WHILE SUTURING



40




Tobias & Johnston
Small Animal Veterinary Surgery 2011

41

STAPHYLECTOMY – CO2 LASER


- PRODUCES FOCUSED INFRARED LIGHT TO ABLATE AND VAPORIZE THE TISSUES
- WAVELENGTH: 10,600 NM
- HIGHLY ABSORBED BY WATER



42

STAPHYLECTOMY – BIPOLAR VSD


- USES ELECTROTHERMAL ENERGY TO DENATURE COLLAGEN AND ELASTIN IN BLOOD VESSEL WALLS AND SEAL VESSELS
- SAME STEPS AS CUT-AND-SEW UNTIL THE CUT AND SEW PORTIONS...




43

FOLDED FLAP PALATOPLASTY


- DESCRIBED IN 2007 BY 2 FRENCH SURGEONS
- (DUPRE) PURPOSE: TO SHORTEN AND THIN THE




45



46



47



48

ODDITY: NORWICH TERRIERS

- ENLARGED SUPRAARYTENOID
- FOLDS NOT SURGICAL
- CAN FIX OTHER BOAS PROBLEMS





Fig. 3. Endoscopic image from a Norwich Terrier showing a large, white, dome-shaped structure with the left arytenoid cartilage. The structure is located in the larynx and is not a foreign body. It is a normal anatomical structure (L) and is not a foreign body.

Johnson, JVIM, 2013

50

EVERTED TONSILS


- TO REMOVE OR NOT TO REMOVE?
- MILDLY EVERTED + SOFT?
 - PROBABLY LEAVE.
- MARKEDLY EVERTED + FIRM?
 - TAKE THEM OUT!



51

EVERTED LARYNGEAL SACCULES

- WHITE SHINY DOME STRUCTURES
- SOFT?
 - LEAVE THEM ALONE.
- FIRM?
 - CONSIDER REMOVING.



52

EVERTED LARYNGEAL SACCULES

Fossum et al. 2012

Complication	Medical Management	Sacculotomy
None	~35	~15
Mild	~10	~10
Moderate	~2	~5
Severe	~1	~2

Complications:
None

Mild: <48 h regurg, mild stertor or stridor w/o dyspnea

Moderate: >48 h regurg, mild cough, episode of spontaneously resolving dyspnea

Severe: dyspnea, regurgitation requiring tx, temp trach, tx for pneumonia, ventilator, euthanasia, death

Hughes et al. JSAP 2018

53

LARYNGEAL ANATOMY

Tobias and Johnston, Veterinary Surgery Small Animal

54

LARYNGEAL COLLAPSE


- STAGE 1
• EVERTED LARYNGEAL SACCULES
- STAGE 2
• MEDIAL DISPLACEMENT CUNEIFORM
- STAGE 3
• MEDIAL DISPLACEMENT CORNICULATE

White, JSAP, 2012

56

POST-OPERATIVE CARE

- HEAD-UP WITH CONTINUED MONITORING
- STERNAL POSITION
- ADDITIONAL INDUCTION AGENTS AND TRACHEAL TUBES
- PREPARE FOR A TEMPORARY TRACHEOSTOMY
- COOL ENVIRONMENT
- MINIMIZE RESTRAINT
- PLAN SURGERY AND SEDATION IN THE AM
- HOSPITALIZE FOR "RESPIRATORY WATCH" OVERNIGHT



62

POST-OPERATIVE CARE

- SINGLE DOSE OF ANTI-INFLAMMATORY STEROID 0.15MG/KG DEX SP
- SEDATION AS NEEDED
 - DEXMED CRI 0.5 – 2 UG/KG/HR
- OVERNIGHT MONITORING RECOMMENDED
- MAJOR COMPLICATION RATE ~7%
 - ASPIRATION PNEUMONIA ASSOCIATED WITH MAJOR COMPLICATIONS

63

SURGERY: POTENTIAL COMPLICATIONS

- RESPIRATORY DISTRESS / OBSTRUCTION IN THE IMMEDIATE POST-OP PERIOD
- RE-INTUBATE.
- WHAT TO DO IF DOG CANNOT BE EXTUBATED?! TEMP TRACH.

RESPIRATORY


- CONTINUED STERTOR/STRIDOR
- UPPER AIRWAY OBSTRUCTION
- ASPIRATION PNEUMONIA
- RHINITIS

GASTROINTESTINAL

- REGURGITATION
- VOMITING

- INCISIONAL COMPLICATIONS
- DEATH USUALLY <5%

66




WHAT CAN GO WRONG?

- INFLAMMATION, RE-OBSTRUCTION, NOT REMOVING ENOUGH TISSUE
- REMOVING TOO MUCH TISSUE
- KEY: BE PREPARED FOR RE-INTUBATION AND POTENTIALLY A TEMPORARY TRACHEOSTOMY.

67

What if they Obstruct after Extubation?

- Sternal, pull tongue cranially, open mouth
- Supplemental oxygen
- Sedatives or Reversal?
- Anti-inflammatories
- Reintubate
- Nasotracheal Oxygen
- Other Surgical Procedures
 - Sacculectomy
 - Temporary Tracheostomy
 - Cricothyroid lateralization
 - Permanent Tracheostomy




Senn JVECC 2011

68

POST-OP OBSTRUCTION? TEMP TRACH.


- FIRST, RE-INTUBATE IF AT ALL POSSIBLE.
- WARN ALL BOAS CLIENTS FOR POSSIBLE NEED TO PERFORM TEMPORARY TRACHEOSTOMY POST-OP (OR ANY TIME IN HOSPITAL)
- WHEN IN DOUBT, PLACE A TRACH.



69

SURGERY: POTENTIAL COMPLICATIONS


- ALWAYS BE READY TO RE-INTUBATE
- READY FOR A TEMPORARY TRACHEOSTOMY



70

TEMPORARY TRACHEOSTOMY

- INCISE BETWEEN TRACHEAL RINGS 3-5 ON THE VENTRAL SURFACE
- PLACE STAY SUTURES AND MARK "UP" AND "DOWN"
- DON'T INFLATE TRACH TUBE CUFF UNLESS VENTILATING




Tobias, Manual of soft tissue surgery

71

TRACHEOSTOMY TUBES


- INNER CANNULA ALLOWS FOR LESS STRESSFUL CHANGES
- SMALLEST SIZES DO NOT COME WITH THIS CANNULA



72

TRACHEOSTOMY TUBES - HOMEMADE

- REMOVE END THAT ATTACHES TO OXYGEN CUT THE PLASTIC TO CREATE FLAPS
- REPLACE CAP AT DESIRED LENGTH PLACE HOLES IN FLAPS TO ATTACH UMBILICAL TAPE TO TIE TO NECK OF ANIMAL



73

LARYNGEAL COLLAPSE

- SURGICAL INTERVENTION
 - MODIFIED TIE-BACK
 - TEMPORARY TRACHEOSTOMY



74

NASOTRACHEAL INTUBATION



75



76



77

WHAT IF THEY DON'T IMPROVE AFTER SURGERY?

- REASSESS AND TREAT THE TREATABLE
- THINGS SEVERE LARYNGEAL COLLAPSE
- ABERRANT NASAL TURBINATES
- SLEEP APNEA
- WEIGHT LOSS
- THICKENED SOFT PALATE

83

SUMMARY

- TREAT EARLY PREVENT/MINIMIZE LARYNGEAL COLLAPSE TREAT
- THE TREATABLE PROBLEMS
- KEEP IT SIMPLE
- GRADE 3 LARYNGEAL COLLAPSE—GUARDED PROGNOSIS

84

THANK YOU!

THANK ALL OF YOU!

- THANK YOU TO THE CLIENTS, PATIENTS, AND WONDERFUL TECHNICIANS!

•SURGICAL DESCRIPTIONS AND TECHNIQUES AVAILABLE IN:

TECHNIQUES IN SMALL ANIMAL SOFT TISSUE, ORTHOPEDIC, AND OPHTHALMIC SURGERY

TEXTBOOK COMING SOON IN 2024

85

QUESTIONS?



MIEL



LILLIPUTIAN & LUDWIG



KELEV



86

OPHTHALMOLOGY



ROBIN SANKEY
DVM, DACVO


Dr. Robin Sankey is a board-certified veterinary ophthalmologist. She earned her doctor of veterinary medicine degree from Colorado State University in 2001. Dr. Sankey owned and managed a small animal practice in New Mexico for 13 years. In 2014, she was chosen for a coveted residency position in Comparative Veterinary Ophthalmology at the Animal Ophthalmology Clinic in Dallas.

While Dr. Sankey is proficient in all aspects of ophthalmology, her clinical focus revolves around ocular manifestations of systemic diseases. Beyond her professional dedication, she finds joy in hiking, exploration with her husband and children, engaging in community service projects, gardening, and indulging in crafting during her free time.



ROBIN.SANKEY@GCVS.COM
713-693-1111

Corneal Anatomy




Source: <https://vetiankey.com/corneal-ulcers/>



- **Corneal Epithelium:**
 - Nonkeratinized, stratified squamous epithelium
 - 25-40 micrometers thick (dogs and cats)
- **+/- Bowman's Layer:**
 - Humans and Non-human Primates
- **Corneal Stroma:**
 - Makes up 90% of corneal thickness
 - Made up of transparent lamellae of collagenous tissue
 - The precise arrangement is important for maintaining corneal clarity

(Source: Veterinary Ophthalmology 6th ed)

Corneal Anatomy



Source: <https://vetiankey.com/corneal-ulcers/>




- **Descemet's Membrane**
 - Basement membrane for the endothelium
- **Endothelium**
 - A single layer of cells lining the inner cornea
 - Loss leads to corneal edema, up to 500x thicker (corneal endothelial degeneration)

(Source: Veterinary Ophthalmology 6th ed)

Corneal Properties and Anatomy

- Richly supplied by nerves
- Innervated by the long ciliary nerve, which is derived from the ophthalmic branch of the trigeminal nerve
- Superficial layers are innervated primarily by pain receptors, while the stromal layer is primarily innervated by pressure receptors
- Nutrition supplied by the tear film and aqueous humor
- Protection supplied by the eyelids and nictitating membrane



What Makes the Cornea Transparent?

- Lack of blood vessels
- Nonkeratinized surface epithelium maintained by the pre-corneal tear film
- Lack of pigmentation (melanin)
- Relative dehydration (deturgescence)
- Size and organization of stromal collagen fibrils
- The goal is to promote healing in a way that will allow the cornea to return to as close to transparent as possible





Image and info from Gelatt's Veterinary Ophthalmology, 6th ed



Signs of Corneal Ulceration

- Blepharospasm (Squinting)
- Conjunctival hyperemia
- Discharge
- Corneal vascularization (4-7 day lag period)
- Corneal edema
- +/- Hypopyon



<https://doi.org/10.3389/fvets.2021.641265>



Depth Matters




If Unable to Refer Immediately....

- Ofloxacin and Neo-Poly-Bac/Neo-Poly-Gram every 2 hours
- Amniotic Extract if available/Serum
- +/- Atropine (not if ruptured, glaucoma, or low tears)
- E-collar
- Harness only (no collar) if deep or ruptured and limit activity
- Systemic antibiotic if ruptured or worried about rupture



Reflex Uveitis and Hypopyon

- Hypopyon is an accumulation of leukocytes in the anterior chamber
- Can occur due to corneal ulcers, corneal abscesses, uveitis, and systemic illnesses
- Stimulation of corneal nerves can cause the release of prostaglandin, which can lead to reflex anterior uveitis
- Due to leaking of the normally tight junctions in the iris/ciliary body of the eye secondary to intraocular inflammation which allows increased leaking of protein and potentially WBC's, which leads to hypopyon



White arrow: indolent ulcer
Grey arrow: Severe iris atrophy
Red Arrow: Hypopyon

Image from DJ Haessler, Jr, DVM, MS, DACVO, The Animal Eye Institute, Cincinnati, Ohio
OPHTHALMOLOGY: CLINICIAN'S BRIEF
(JULY 2016)



Only Debride If You Can Answer YES To One Of Two Questions...

1. IS THIS A SUPERFICIAL INDOLENT ULCER WITH NO INFECTION PRESENT?



YES!



NO!

2. IS THIS A SUPERFICIAL NON-HEALING FELINE HERPETIC ULCER WITH LOOSE EDGES THAT HAS ALREADY UNDERGONE TREATMENT?



CRITICAL CARE



MELISSA LACAZE
DVM, DACVECC

Dr. A. Melissa Garcia-Lacaze received her doctor of veterinary medicine from Texas A&M University in 1998. She then completed a one-year emergency and critical care internship, followed by a three-year emergency and critical care residency at the Animal Emergency Center in Glendale, Wisconsin. Dr. Lacaze joined Gulf Coast Veterinary Specialists in 2002, and became board certified by the American College of Veterinary Emergency and Critical Care in 2003. Dr. Lacaze has a mixed-breed dog, Mungo, and two cats, Nimo and Diamond.



MELISSA.LACAZE@NVA.COM
713-693-1111

Canine transfusion medicine



DEA 1.1, 1.2, 2, 3, 4, 5, 6, 7 and 8




No naturally occurring antibodies - so reactions to first time transfusions are rare



DEA 1.1, 1.2 and 7 are the most antigenic




Canine transfusion medicine



Blood type



Crossmatch to determine if unit is compatible



Only perform if patient is stable!




TRANSFUSION PEARL - life threatening hemorrhage



Large bore, short catheter



Crossmatch type not necessary



If patient has had previous transfusion and no type/crossmatch can be done, use negative





Sometimes Type B cats are not exotic breeds



ALWAYS make sure to type cats prior to a transfusion!



Lined writing area for notes.

TRANSFUSION PEARL



Most cats are Type A.....easy to remember cAt



Standard of care to type and crossmatch all feline blood transfusions




Type cats for plasma transfusions, administer appropriate type - concerns for RBC fragments



Lined writing area for notes.

What do I give?

Rule of thumb: Give what the pet is losing!



Blood loss: whole blood



Hemolytic anemia: pRBC



Coagulopathy: plasma OR whole blood



Lined writing area for notes.

Transfusion Pearl




Anti-coagulant Rodenticide Ingestion

- ▶ Bleeding due to lack of active clotting factors
- ▶ Antidote: vitamin K
- ▶ Transfusion treatment: fresh frozen plasma OR whole blood
- ▶ If you only have frozen plasma - it will still provide vitamin K dependent clotting factors!



Transfusion Pearl



Plasma to replace albumin

- ▶ Not long-term solution
- ▶ Questionable improvement in outcome
- ▶ Very expensive
- ▶ Focus on treating the cause of the loss



Transfusion Pearl



Platelets to treat IMTP

- ▶ Very expensive
- ▶ Same process destroys transfused platelets
- ▶ Lyophilized platelets - no longer available
- ▶ Platelet rich plasma for life threatening bleeding
- ▶ Focus on treating the cause of the loss



When do I give a transfusion?

There is no magic number!

- Clinical appearance
- Age of patient
- How quick was the loss
- Continued blood loss
- Anticipated blood loss
- At 15%, concerns for tissue oxygenation





Transfusion Pearl

- ▶ In patients with suspected blood loss:
 - ▶ Always evaluate BOTH PCV/TP
 - ▶ Splenic contraction causes PCV to remain elevated while TP drops
 - ▶ Be proactive - don't wait for the PCV to drop!



How Fast Do I Give a Transfusion?

- ▶ How fast was the loss?
- ▶ Current clinical condition
- ▶ Concurrent health disease
- ▶ Patient's fluid status
- ▶ Can bolus from the bag
- ▶ Can bolus in a syringe with filter
- ▶ If given as an infusion - do not leave unrefrigerated for longer than 4-6 hours



How much do I give?



Whole blood and pRBC

- ▶ Patient size
- ▶ Amount of blood lost
- ▶ Is there ongoing loss?

Plasma: typically start at 20ml/kg/day and re-evaluate



How much do I give?


Volume of WHOLE BLOOD to administer:

$$\text{kg} \times \frac{\text{desired PCV} - \text{recipient PCV}}{\text{donor PCV}} \times \begin{matrix} 90 \text{ (dogs)} \\ 70 \text{ (cats)} \end{matrix}$$



Transfusion Pearl

1ml per lb. will increase the PCV by 1%



5lb. Patient

Current PCV 10% - goal is 25%
That is an increase of 15%

It will take 5ml to increase the PCV 1%

5ml * 15 = 75ml WHOLE BLOOD needed

pRBC (50% volume needed) = 37.5ml



Transfusion Reactions Acute Immunologic

Acute hemolysis - Treatment

- ▶ Slow or stop the transfusion
- ▶ Support HR, blood pressure with IV fluids
- ▶ Corticosteroids are not indicated



Transfusion Reactions Acute Immunologic

Allergic Reaction

- ▶ Type 1 reaction: mast cell degranulation resulting in release of vasoactive substances
- ▶ Reactions to plasma are more severe



Transfusion Reactions Acute Immunologic

Allergic Reaction

- ▶ Vomiting/diarrhea
- ▶ Urticaria
- ▶ Erythema
- ▶ Pruritis
- ▶ Facial swelling
- ▶ Can result in anaphylactic shock (hypotension, tachycardia, bronchoconstriction)



Transfusion Reactions Acute Immunologic

Febrile Reactions

- ▶ Most common type of reaction
- ▶ Reaction of donor antigen to recipient antibodies
- ▶ Typically self-limiting or responds to slowing the transfusion



Transfusion Reactions Acute Immunologic

Transfusion Related Acute Lung Injury (TRALI)

- ▶ Typically within 1-6 hours of transfusion, not known to occur in cats
- ▶ Bilateral pulmonary infiltrates, fever +/- hypotension
- ▶ Adherence of leukocytes to pulmonary endothelium
- ▶ Cannot distinguish from ARDS
- ▶ Low mortality rate with supportive care
- ▶ Must differentiate from transfusion associated circulatory overload (TACO)



Transfusion Pearl

TACO

- ▶ Physical exam: jugular distension
- ▶ Chest radiographs: pulmonary venous distension
- ▶ TFAST: enlarged caudal vena cava or intrahepatic venous distension
- ▶ Protein content of fluid: low (<3.0)
- ▶ Treatment: stop fluids / furosemide

TRALI

- ▶ Physical exam: no jugular distension
- ▶ Chest radiographs: no pulmonary venous distension
- ▶ TFAST: no enlarged caudal vena cava or intrahepatic venous distension
- ▶ Protein content of fluid: high (>3.5-4)
- ▶ Treatment: supportive care / oxygen



INTERNAL MEDICINE



MELANIE PUCHOT DVM, DACVIM

Dr. Melanie Puchot is a Texas native who received her veterinary degree from Texas A&M University College of Veterinary Medicine in 2013. After graduation, she completed a small animal rotating internship at Cornell University in Ithaca, NY. She then returned to Texas A&M University and completed a 3-year residence in small animal internal medicine finishing in 2017. Dr. Puchot then joined a specialty hospital in New Jersey for four years before coming back to her hometown of Houston. She has a particular interest in endocrinology, nephrology, and interventional endoscopy/radiology.



During her free time, she enjoys spending time with her wife, Diane, camping, and working towards the goal of visiting all the national parks. She has two pets: a dog named Onyx and Cat named Sprite.



MELANIE.PUCHOT@GCVS.COM
713-693-1111

Pathophysiology




- No longer rare
- Premature activation of digestive enzymes
- Pancreatic autodigestion
- Acute vs chronic
- Inflammation in surrounding organs



Pathophysiology


- | | |
|--|--|
| <p>Acute</p> <ul style="list-style-type: none"> • Trypsinogen activation • NFkB pathway • Influx of neutrophils • Hypoperfusion and thrombosis • Biliary reflux / circulation • Bacterial cholangitis | <p>Chronic</p> <ul style="list-style-type: none"> • Acute can lead to chronic • Pancreatic stellate cells <ul style="list-style-type: none"> • Fibrosis • Trypsin activation independent • Cholecystokinin and oxidative stress • Ductal obstruction or ductal epithelial damage |
|--|--|

Acute pancreatitis



Role of Bacteria

- FISH identified bacteria in 35% of pancreas
 - Moderate to severe pancreatitis
 - Acute >> Chronic
- Reflux from duodenal papilla
- Intestinal translocation
- No evidence supports clinical relevance
- No antibiotics unless concurrent illness
- Rare pancreatic abscess




Clinical Signs

- Vague
- Lethargy
- Hyporexia
- Vomiting
- Weight loss
- Icterus
- Diarrhea
- Dyspnea
- Rarely, abdominal pain



Physical exam findings



- Dehydration
- Hypothermia
- Icterus
- Abdominal mass effect
- Pallor
- Tachypnea
- Fever
- Abdominal pain



Chemistry Panel

- Variable
- Liver enzyme elevation
 - ALT, AST, and bilirubin
- Azotemia
- Isosthenuria
- Hypoglycemia or hyperglycemia
- Electrolyte abnormalities: hypokalemia, hyponatremia, and hypocalcemia
- No dyslipidemia expected



Pancreatic enzyme testing

- Enzymes normally leaked into vascular
- Increased inflammation → increased leakage
- Amylase / Lipase
 - Not specific; DON'T USE
- Pancreatic specific lipases
 - DGGR (PSL; Antech)
 - fPLI (Iddex / TAMU GI Lab)
- Trypsin-like immunoreactivity




Ultrasound: Acute Pancreatitis

- Low sensitivity
 - Better in moderate to severe cases
- Hypoechoic and enlarged pancreas
- Hyperechoic mesentery
- Focal abdominal effusion
- Duodenitis
- Operator dependent results




Pancreatic sampling




- FNA of focal abnormalities
- Laparoscopic or surgical biopsies
- Less commonly done in acute cases
- Unlikely to exacerbate pancreatitis
- Acute: Neutrophilic and fat necrosis
- Chronic: Fibrosis and lymphocytic
- Evaluate for concurrent illnesses



Management of Acute Pancreatitis




- Treat inciting cause
 - Most are idiopathic
- Supportive care
 - IV Fluids
 - Anti-emetics
 - Analgesia
 - Electrolyte abnormalities
- Management of complications
- Specific treatments on horizon?



PANOQUELL®-CA1

(fuzapladi sodium injection)



CANINE ONLY, NOT IN CATS

PANOQUELL-CA1
(fuzapladi sodium injection)

For information use in dogs only. Researchable before using.

PANOQUELL-CA1 is a leukocyte function-associated antigen 1 (LFA-1) receptor inhibitor. Indicated for the management of clinical signs associated with acute onset of pancreatitis in dogs. Contraindicated for use in cats. Caution: Administration of fuzapladi sodium injection may cause hypotension in dogs. Do not use this product other than as directed in the labeling. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DERMATOLOGY



KARIN BEALE
DVM, DACVD

Dr. Karin Beale earned her Bachelor of Science in biology and Doctor of Veterinary Medicine degrees from the University of Florida in 1985. After a year of small animal private clinical practice in Washington, D.C., her passion for dermatology emerged. She pursued a residency in veterinary dermatology at the University of Florida, achieving board certification.


For four years, she served as an assistant professor of veterinary dermatology at the University before establishing Gulf Coast Veterinary Dermatology and Allergy. Dr. Beale's expertise extends to infectious skin and ear conditions, as well as managing allergic patients. Beyond her professional commitments, she shares her home with her youngest daughter and two Golden Retrievers. Dr. Beale is fluent in French as a second language and enjoys travel, both for personal enjoyment and educational opportunities. In her leisure time, she channels her creativity into artistic ventures, such as painting and crafting jewelry.



KARIN.BEALE@GCVS.COM
713-693-1111

histopathology

- Subcorneal or intracorneal pustules with neutrophils, +/- eosinophils, acantholytic cells.
- There may be outer root sheath involvement.



Treatment of feline PF

Glucocorticoids

- Prednisolone 2-4mg/kg induction qd
- Triamcinolone 0.6-2mg/kg induction qd

Immunomodulatory therapy

- Steroid sparing effects
- Chlorambucil 0.1-0.2mg/kg qd-qod
- Modified CsA 7-10mg/kg +
- Oclacitinib 1mg/kg q 12



CsA is a good steroid sparing agent in cats with PF

- Cyclosporine provided greater steroid-sparing effects than chlorambucil
- 6/8 patients managed with CsA were ultimately managed with no GCC. This was only true in 1/7 patients with chlorambucil.
- Starting dose 7-10 mg/kg qd
- Median maintenance dose 5.4mg/kg twice weekly to daily.

7 Vet Dermatol. 2012 Oct;23(5):403-476. doi: 10.1111/j.1365-3144.2012.01069.x. Epub 2012 Jun 25.

Use of modified ciclosporin in the management of feline pemphigus foliaceus: a retrospective analysis

Katharine E Innes¹, Karin M Beale, Valerie A Faddy

Oclacitinib has also been described in the treatment of feline pemphigus foliaceus

Veterinary Dermatology

1st December 2021 DOI: 10.1111/vde.12949
Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus
Isabel Carrasco*  María Martínez* and Gloria Albóyanar



Immunomodulatory therapy in cats

- Discussion of recrudescence of latent toxoplasmosis (or novel)
- Outdoor hunting cats?
- Avoid raw diets

Case Reports > Vet Dermatol. 2022 Oct;33(5):435-439. doi: 10.1111/vde.13097.
Epub 2022 May 29.

Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome

Alexandra Moore¹, Amanda K Burrows¹, Richard Malik², Rudayna M Ghubash², Robert D Latt⁴, Benjamin Remaj⁴

Steroid monotherapy in cats with PF

Prednisolone as monotherapy with a median induction dose of 2mg/kg daily led to remission in 97% of cats within 8 weeks.

Monotherapy with triamcinolone is more likely to induce remission sooner than prednisolone.



Calhoun, 7 yr MC black lab



- No prior history of skin disease.
- Recent (4 week) onset of painful, crusty footpads.
- Current medications
 - Carprofen (osteoarthritis)
 - Heartguard
 - Nexguard




Calhoun

- Malaise
- Fever 103.1F
- Pain
- Decreased appetite
- No other lesions other than on pads

- DDX:
 - Pemphigus foliaceus
 - SND/hepatocutaneous syndrome

- Plan:
 - Biopsy
 - CBC, Chem, UA



Calhoun

- Biopsy: subcorneal pustular dermatitis compatible with PF.
- Crusts contain layers of neutrophils, acantholytic cells
- Neutrophilia, normal BUN, albumin, ALT.

- Therapy initiated with prednisone 2mg/kg BID for 10 days
- Phone follow up: significant improvement! Reduce to 1.5mg/kg bid, then 1.5 mg/kg qd



CARDIOLOGY



ERIC OWENS
DVM, DACVIM

Dr. Eric Owens is a board-certified cardiologist from Chicago. He studied at the University of Notre Dame and then earned his Doctor of Veterinary Medicine from St. George's University, with clinical training at North Carolina State University. Dr. Owens completed a small animal internship at The Ohio State University. Thereafter, he completed a cardiology internship and a cardiology residency at Oregon State University.

His clinical interests include interventional cardiology and congenital cardiac disease, and his research interests include advanced cardiac imaging modalities, utilization of endovascular and minimally invasive therapies, and cardiomyopathic disease in dogs.



ERIC.OWENS@GCVS.COM
713-693-1111

Degenerative Valve Disease: Practical Guide to Management

Eric Owens, DVM, DACVIM (Cardiology)
Gulf Coast Veterinary Specialists




Outline


- Why does CDVD matter?
- Review mitral valve disease
- Clinical course
- Medical therapy
- Complications and outcomes
- New therapy




Importance




Prevalence



Mitral Valve Leaflets




Myxomatous Degeneration




1. Degeneration of the fibrosa
-collagen and elastin dissolution/disorganization
2. Thickened spongiosa
-hyaluronic acid, chondroitin sulfate accumulations
3. Endothelial damage
4. Hemorrhage, edema




Pathophysiology



Pathophysiology





Physical Exam

Grade 1-6 Scheme	Simplified Scheme
Grade 1/6	Soft
Grade 2/6	
Grade 3/6	Moderate
Grade 4/6	Moderate / loud
Grade 5/6	Loud / thrilling
Grade 6/6	



Murmur Intensity and Severity





FIG 1. Increasing murmur intensity is associated with increasing left atrial size, as determined by the left atrial-to-aortic ratio (LA:Ao). The black line denotes the median value, the box denotes the interquartile range (IQR (25th to 75th percentile)), the circles denote values greater than 1.5 times the IQR greater than the 75th percentile. Numbers above the category labels denote the sample sizes in each category. All groups were different from each other (P<0.05).



• Lyungvall I, et al. J Sm Anim Pract. 2014;55:545-550

Grade 1-6 Scheme	Simplified Scheme
Grade 1/6	Soft
Grade 2/6	
Grade 3/6	Moderate
Grade 4/6	Moderate / loud
Grade 5/6	Loud / thrilling
Grade 6/6	



Echocardiography

- Confirm suspected disease
- Quantify severity of regurgitation
- Assess LV and LA chamber sizes
- Assess LV function
- Estimate LA/pulmonary venous pressure
- Assess for concurrent diseases

Monitoring Disease Progression

- Best diagnostic test = Thoracic radiographs
 - Monitor increase in left ventricular and left atrial size
- Soft murmur/Mild LAE: Recommend every 12-24 months
- Moderate murmurs/LAE: Recommend every 6-9 months
- Loud murmurs/Severe LAE: Recommend every 3-4 months



Therapy

Therapy of CDVD

- Asymptomatic dogs
 - Without heart enlargement
 - With enlargement
- Symptomatic dogs
 - Congestive Heart failure
 - Left sided: Pulmonary Edema
 - Right sided: Pleural effusion, Ascites
 - Complications



Review CDVD staging

Stage A - no murmur or echocardiographic abnormality	Stage B - heart murmur or echocardiographic abnormality	Stage C - congestive heart failure	Stage D - advanced heart failure
<ul style="list-style-type: none"> • Higher than average likelihood of development of disease 	<ul style="list-style-type: none"> • B1 - range from no heart enlargement to enlargement not meeting B2 criteria • B2 - VHS >10.5, LA:Ao 1.6, LVIDdN 1.7, grade 3/6 murmur or louder 	<ul style="list-style-type: none"> • Furosemide • ACEi • Pimobendan • Spironolactone 	<ul style="list-style-type: none"> • > 8 mg/kg/day furosemide • Torsemide



- Stage A
 - No specific therapy
 - Annual evaluation for high-risk breeds
- Stage B1
 - No specific therapy
 - Recheck every 6-12 months
- Stage B2
 - Pimobendan 0.25-0.3 mg/kg BID
 - Dietary
 - ACEi - no consensus
 - Beta-blockers, spironolactone, amlodipine in specific circumstances
 - Surgical intervention

Preclinical therapy

ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs

Bruce W. Keane¹ | Clarke E. Atkins¹ | John D. Bonagura^{2,3} | Philip R. Fox⁴ |
 Jens Häggström⁵ | Virginia Luis Fuentes¹ | Mark A. Oyama⁶ | John E. Rush⁷ |
 Rebecca Stepien⁸ | Masami Uechi⁹






Fig 2. Kaplan-Meier survival curve plotting the estimated percentage of dogs in each group in the pre-protocol population that have not yet met the primary endpoint (congestive heart failure or cardiac death) against time. There were 176 dogs in the pimobendan group and 176 dogs in the placebo group at the outset. CI, confidence interval; NA, not able to calculate.




Fig 3. Kaplan-Meier survival curve plotting the estimated percentage of dogs in each group in the pre-protocol population that were not yet experienced an event (defined as having reached the primary endpoint, undergone euthanasia or died for a noncardiac cause, had chronic medications initiated (Furof 1 or Furof 2), had congestive heart failure endpoint that was not verified by the adverse committee, the owner became noncompliant with study instructions, or that dog was withdrawn from the study by the owner or emergency against time. There were 176 dogs in the pimobendan group and 176 dogs in the placebo group at the outset. CI, confidence interval.

ACVIM stage B2

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial



Preclinical ACE inhibitors

- Preclinical ACE inhibitors are controversial
 - DELAY (2020) study, SVEP (2002) trial did not demonstrate benefit
 - VETPROOF (2007), Puchelon et. al (2008) demonstrated benefit
- Some clinicians start ACE-inhibitor before CHF, others do not
- ACVIM consensus statement: 5 (of 10) panelists recommend treatment with ACEI (weak level of evidence)




Fig 4. Percentage of dogs in the study versus time. The difference in number of days in the study between placebo and enalapril-treated dogs was not significant even when the analysis was restricted to dogs with normal heart size at study onset ($P = 0.85$) or to dogs with cardiomegaly (analysis of cardiomegaly at entry only) (dog with last $P = 0.56$).



Acute congestive heart failure

- Most common signs: tachypnea, dyspnea, cough
- Other signs:
 - Reduced appetite
 - Exercise intolerance
 - Syncope
- Diagnosis?
 - History
 - Physical exam, **HR**
 - Chest radiographs





GIC GULF COAST
VIS VETERINARY
SPECIALISTS

Acute CHF

Pulmonary edema:

- Oxygen
 - 40-50% inspired oxygen desired
 - Oxygen cage (small dogs)
 - Nasal canulas (large dogs)
- Furosemide
 - IV is best
 - IM, SQ if unstable
- Pimobendan – if possible
- +/- nitroprusside
- +/- nitroglycerin
- +/- dobutamine

Management of acute CHF

- Lasix protocol:
 - Mildly decompensated dog: 2 mg/kg IV initial dose
 - Moderately decompensated dog: 2-4 mg/kg IV initial dose
 - Severely decompensated dog: 4-6 mg/kg IV initial dose
- Reassess respiratory rate and effort every 30 minutes
 - Try to reduce dose on subsequent injections
 - May repeat dose every 1-2 hours and then spread out frequency ...q 4 hours, q 6 hours, q 8 hours
 - Max ~ 12-16 mg/kg/day

GIC GULF COAST
VIS VETERINARY
SPECIALISTS

Management of acute CHF

- When dog is stable:
 - IV catheter placement
 - Draw blood to assess renal values
 - Thoracic radiographs to assess severity of pulmonary edema
- Debate over repeated boluses vs. CRI of furosemide
 - Pros: More consistent diuresis, less potassium loss
 - Cons: Requires concurrent fluid administration
Requires syringe pump
No reported treatment benefit to CRI
- My personal preference is intermittent bolus dosing

GIC GULF COAST
VIS VETERINARY
SPECIALISTS

Acute respiratory distress

- Sedation
 - Sedation may be necessary....and life saving.
 - Butorphanol: 0.05-0.4 mg/kg IM or SQ
 - Usual dose 0.1-0.2 mg/kg
 - Acepromazine: 0.005-0.02 mg/kg
 - Usual dose: 0.01 mg/kg



Management of acute CHF

Monitoring and discharge

- Hourly respiratory rate and effort
- Heart rate every 4-6 hours
- Avoid any extra fluid administration
- Free access to water unless profound distress
- Repeat imaging 12-24 hours into therapy
- Once breathing normally and drinking = able to discharge
 - I like to have them eating too
- Repeat chest x-rays prior to discharge (ideal)
 - Or can send home and repeat them at 1 week recheck




Chance of success?

- High survival rate to discharge for 1st time Acute CHF
- Open conversation with owners regarding:
 - Need for life-long oral medications
 - Financial and emotional investment
 - Possibility and expectation of recurrent HF
 - Possibility of arrhythmia complications
 - Possibility of sudden death
- Long term prognosis: Average of ~ 1 year



Chronic Therapy of CDVD




Chronic CHF treatment


- Furosemide
- ACE-inhibitor
 - Enalapril or benazepril
 - Starting dose: 0.3-0.4 mg/kg PO BID
 - Assess renal values before and 1 week post
 - If CREA inc > 15%:
 - Reduce dose to 0.2 mg/kg PO BID



ACE Inhibitors



Enalapril



Benazepril



Chronic CHF treatment

- Furosemide
- ACE-inhibitor
- Pimobendan
 - All dogs with documented CHF
 - Dose: 0.3 mg/kg PO BID
 - Up to 1 mg/kg TID for advanced, refractory cases



Pimobendan





Inodilator

Benefits:

- Improves clinical signs
- Increases exercise tolerance
- Improves survival



Pimobendan



Hägglström J, et al. The QUEST Study. J Vet Int Med 2008 22:1124-1125




Chronic CHF treatment

- Furosemide
- ACE-inhibitor
- Pimobendan
- Spironolactone
 - Dose: 0.5-4 mg/kg PO SID-BID
 - Used as a second diuretic with furosemide
 - Sequential nephron blockade (collecting duct)
 - May help manage hypokalemia



Refractory CHF therapy

- Furosemide, pimobendan, ACEi, spironolactone
- Still having episodes of CHF...what now??
 - Change: Switch from furosemide to torsemide
 - More potent loop diuretic (10x), but less info known
 - Dose: 0.2 mg/kg SID-BID
 - Change: SQ admin of furosemide
 - Add: Hydrochlorothiazide: uptitrate to 2-4 mg/kg PO BID
 - Add: Amlodipine (0.1 mg/kg SID) or Hydralazine (0.5-2 mg/kg BID)



Chronic or refractory CHF therapy

- What else can we do that is helpful?
- Intermittent fluid removal: pleural or peritoneal
 - Optimization of all arms of therapy
 - Diuretics: Sequential nephron blockade
 - RAAS inhibition
 - Cough suppressants for "intractable cough"
 - Ensure no active pulmonary edema
 - Hydrocodone: 0.2 mg/kg PO q6-12 hours
 - Lomotil 0.2 mg/kg q8h
 - Butorphanol: 0.05-1.0 mg/kg PO q 6-12 hours



Arrhythmias



Atrial Premature Contractions (APCs)



- No specific therapy required or initiated for APCs
- But...important clue that more severe arrhythmias may be develop in near future



Atrial fibrillation



1. No P waves
2. Irregularly irregular
3. Supraventricular
4. Tachycardic




Atrial fibrillation



- Loss of atrial kick + tachycardia → Decreased cardiac output
- Therapy: Digoxin: 0.003-0.005 mg/kg PO BID
Diltiazem: 1-2 mg/kg PO TID
or extended-release diltiazem: 2-3 mg/kg PO BID






Ruptured Chordae Tendineae

- Acute pulmonary edema
 - Often without commensurate left-heart enlargement
- Collapse, cyanosis
- Variable murmur
- Sudden death



GULF COAST
VETERINARY
SPECIALISTS



Ruptured Chordae Tendineae

- Require aggressive therapy and hospitalization
- Survival rate to discharge: ~50%
- May shorten prognosis

Chordae tendineae Rupture in Dogs with Degenerative Mitral Valve Disease: Prevalence, Survival, and Prognostic Factors (114 Cases, 2001-2006)



GULF COAST
VETERINARY
SPECIALISTS

Treatment of Congestive Heart Failure with Intravenous Nitroglycerin in Three Dogs with Degenerative Valvular Disease

Dr. Arnel, DVM, Andy Cesar, DVM, DACVPC, Robert A. Savarin, DVM, DACVIM



- Nitroprusside
 - 2-10 $\mu\text{g}/\text{kg}/\text{minute}$
 - Start low and increase if needed
 - Potent mixed vasodilator
- Nitroglycerin
 - 1-6 $\mu\text{g}/\text{kg}/\text{minute}$
 - Start low and increase if needed
 - Venous vasodilator
- Hydralazine – onset 1 hour, peak 3 hours
- Amlodipine – peak effect 4-7 days, not recommended
- Furosemide
 - High doses needed initially
 - ~4 mg/kg boluses



GULF COAST
VETERINARY
SPECIALISTS

DIAGNOSTIC IMAGING



KATIE PANSINI
DVM



KYLE PFIEFER
DVM

Orthopedic Problems in General Practice: Radiograph Physics, Positioning, and Common Diseases

Dr. Katie Pansini and Dr. Kyle Pfeifer




Table of Contents

- General physics of radiography
 - Heel effect, plate locations
- Developmental diseases
 - Positions for best interpretation
 - Osteochondrosis/ osteochondritis dissecans
 - Panostitis
 - Hypertrophic osteodystrophy
 - Humeral intracondylar fissures
- Degenerative diseases
 - Degenerative joint disease – Hips and elbows
 - Intervertebral disc disease and degenerative spinal changes
 - Feline capital physeal fractures
 - Feline metaphyseal osteopathy
- Trauma
 - Cranial cruciate ligament tears
 - Fractures
 - Physeal fractures
 - Fracture healing



Radiographic technique



- Typical mAs:
- Extremities = 10
 - Spine = 40
- Allows for kVp in the 40-60 range
Increasing kVp by 15% = 2x mAs



Low kVp High mAs
High contrast
Low latitude

High kVp Low mAs
Low contrast
High latitude

Positioning aids



Radiographic Views


- At least 2 orthogonal radiographs
 - 90° from each other
 - Often a craniocaudal or dorsopalmar/plantar and mediolateral views.
- Additional views
 - Oblique views
 - Flexed/extended
 - Stressed views
- Collimated to the region of interest



Radiographic Views




Osteochondrosis / Osteochondritis Dissecans




Panosteitis

- Self-limiting
- Males > Females
- Large and giant breeds
- Typically between 5 and 12 months of age
- Shifting limb lameness
- Subtle signs, difficult to differentiate from joint pain
- Early phase: Increased medullary opacity near nutrient foramen, with blurring of the medullary trabecular pattern
- Middle phase: Medullary opacities begin to coalesce. Can see a smoothly marginated periosteal reaction.
- Late phase: Resolution of medullary opacities. May see reduced trabecular pattern.



Panosteitis



Hypertrophic Osteodystrophy (Metaphyseal Osteopathy)

- Young, rapidly growing, large dogs
- Swelling of the metaphases of long bones, pain, lameness, pyrexia, depression, and inappetence
- Etiology is still incompletely understood.
- Typically bilaterally symmetric and progressive.



Hypertrophic Osteodystrophy (Metaphyseal Osteopathy)




Incomplete Ossification of the Humeral Condyle

- Also known as humeral intracondylar fissure
- Predominantly in spaniel breeds, though many brachycephalics and other breeds are also affected
- Etiology is not completely understood, and is subject to much debate.
- Most commonly diagnosed by CT, or when the fissure ultimately leads to a fracture
- Occasionally identified on radiographs




Metaphyseal osteopathy

- Similar signalment and history to spontaneous capital physal fractures
- Etiopathogenesis is not completely understood
 - Necrosis and collapse of the femoral neck can occur with either an increase or decrease in vascularization of the femoral neck
- Unclear if related to spontaneous femoral capital physal fractures
 - Often chronic lameness with acute worsening
 - Osteolysis and sclerosis of the femoral neck occurs following capital physal fracture
- Epiphysis is not affected, possibly due to blood supply through the round ligament



Meniscal ossicles


- Occurs along the cranial horn of the medial meniscus and to some extent the cranial intermeniscal ligament
- May be seen alone or with concurrent degenerative changes
- Not typically associated with pain on physical exam
- Was considered an incidental finding



Meniscal Mineralization in Domestic Cats

Mila Freire¹, DVM, James Brown², DVM, Diplomate ACVR, Ian D. Robertson³, BVSc Diplomate ACVR, Anthony P. Pease⁴, DVM, MS, Diplomate ACVR, Jonathan Hash¹, BA, Stuart Hunter², DVM, Diplomate ACVP, Wendy Simpson⁵, DVM, Andrea Thomson Sumrell¹, RVT, and B. Duncan X. Lascelles¹, BSc, BVSc, PhD, DSAS(ST), Diplomate ACVS & ECVS


- Cats with meniscal mineralization were significantly older (10.5 years vs 7.46 years), weighed less (4.57kg vs 5.5kg), and had lower BCS (2/5 vs 3/5)
- Prevalence of 46% in one or both stifles (100 cats)
- No significance in pain scores
- Clear relationship between medial meniscal mineralization and cartilage damage on the medial femoral condyle and medial tibial plateau
 - Unknown if meniscal mineralization is a cause or result of cartilage damage



Elbow dysplasia

Optimal positioning (4 views)

- Mediolateral (in a relaxed standing position)
- Flexed mediolateral
- Craniocaudal
- Craniolateral-15°-caudomedial oblique



https://pubmed.ncbi.nlm.nih.gov/pubmed/20221224/elbow_dysplasia_4.jpg




Ununited anconeal process


- Anconeal process physis closes around 20-22 wks
- Humeral condyle physis closes around 20-32wks



https://www.kitware.com/files/default/2014/03/20140320_1420.jpg




Osteochondritis disicans (OCD)




"Kissing lesion"

Changes to the medial coronoid process



Congruency




Early detection and OFA grading


- Anconeal process is often the first place for osteoarthritis secondary to dysplastic lesions
- Orthopedic Foundation for Animals (OFA) grade
 - Grade 0: No proliferation on anconeal process
 - Grade 1: Up to 3mm
 - Grade 2: 3-5mm
 - Grade 3: >5mm
- Proliferation on the anconeal process may be a normal variant or enthesopathy in some cases



Physeal Fractures



Fracture Healing



Fracture Healing Complications

- Delayed union
- Non-union
- Malunion
- Implant failure
- Infection



Fracture Healing Complications



Thank you.



References

- Boyer, Amanda, Julia M. Klauer, Nicholas S. Keuler, and William M. Adams. "FLIPPY LINE: METAPHYSICAL SCLEROSIS AND CAUDOLATERAL CURVILINEAR AND CIRCUMFERENTIAL FEMORAL HEAD OSTEOPHYTES IN EARLY DETECTION OF CANINE HIP DYSPLASIA." *Veterinary Radiology & Ultrasound* 50, no. 2 (March 2009): 157-66. <https://doi.org/10.1111/j.1749-3846.2009.00209.x>
- Cook, Cristin, and James L. Cook. "Diagnostic Imaging of Canine Elbow Dysplasia: A Review." *Veterinary Surgery* 35, no. 2 (February 2008): 144-53. <https://doi.org/10.1111/j.1532-959X.2008.00481.x>
- Kurai, Chieko M., Anthony P. Frase, Nathan C. Nelson, Greg Habing, and Elizabeth A. Balgopal. "COMPUTED TOMOGRAPHIC IDENTIFICATION OF DYSPLASIA AND PROGRESSION OF OSTEOARTHRITIS IN DOGS ELBOWS PREVIOUSLY ASSIGNED OF GRADES I AND II: Elbow Dysplasia in Of A Grade I and II Elbows." *Veterinary Radiology & Ultrasound* 55, no. 3 (September 2014): 511-20. <https://doi.org/10.1111/avr.12171>
- Lafuente, Pilar. "Young, Male Neutered, Obese, Lane? Non-Traumatic Fractures of the Femoral Head and Neck." *Journal of Feline Medicine and Surgery* 13, no. 7 (July 2011): 498-507. <https://doi.org/10.1098/jfms.2011.02007>
- Morgan, Ian P. "CANINE HIP DYSPLASIA: Significance of Early Bony Spurring." *Veterinary Radiology* 26, no. 1 (January 1987): 2-5. <https://doi.org/10.1111/j.1749-3846.1987.tb01714.x>
- Verhoeven, Geert E.C., Ruth R. Fortin, Luc Duchateau, Jimmy H. Saunders, Bernadette Van Ryssem, Henri Van Bree, and Frank Coopman. "THE EFFECT OF A TECHNICAL QUALITY ASSESSMENT OF HIP EXTENDED RADIOGRAPHS ON INTEROBSERVER AGREEMENT IN THE DIAGNOSIS OF CANINE HIP DYSPLASIA: Effect of a Technical Quality Assessment." *Veterinary Radiology & Ultrasound* 51, no. 5 (September 2010): 498-505. <https://doi.org/10.1111/j.1749-3846.2010.00046.x>
- Wigger, Arno, Bernd Hellmuth, Martin Kramer, and Heike Rudolph. "IMPACT OF FEMORAL HEAD AND NECK CONFORMATION ON HIP DYSPLASIA IN THE GERMAN SHEPHERD DOG." *Veterinary Radiology & Ultrasound* 49, no. 3 (May 2008): 243-48. <https://doi.org/10.1111/j.1749-3846.2008.00356.x>
- Freire, Mila, James Brown, Ian D. Robertson, Anthony P. Frase, Jonathan Heath, Stuart Barber, Wendy Simpson, Andrea Thomas Sumrell, and B. Duncan X. Lancelles. "Metastatic Mineralization in Domestic Cats: Metastatic Mineralization in Cats." *Veterinary Surgery* 39, no. 5 (March 2010): 545-52. <https://doi.org/10.1111/j.1532-959X.2010.00646.x>
- Thrall, Donald E. *Textbook of Veterinary Diagnostic Radiology*. 7th ed. Elsevier, 2018.
- Thrall, Donald E., Robertson, Ian D. Atlas of Normal Radiographic Anatomy and anatomic variants in the dog and cat. 2nd ed., Elsevier, 2011
- Ziveth. <https://www.xraysonline.com/cats/cats-get-scan-1081.html>
- Ullis, SAM. (2015). *DSAA's manual of canine and feline musculoskeletal imaging*. 2nd edn. IM Kolbinger and FJ McCreay. Wiley Blackwell, 2016. 300 pages. Price \$5176.95. ISBN 9781118311977. Australian Veterinary Journal. 96. 10.1016/j.1118311977.12000
- Wall, Corey R., et al. "DIAGNOSTIC SENSITIVITY OF RADIOGRAPHY, ULTRASOUNDOGRAPHY, AND MAGNETIC RESONANCE IMAGING FOR DETECTING SHOULDER OSTEOCHONDROSIS/OSTEOCHONDROSIS DISSEMINANS IN DOGS." *Veterinary Radiology & Ultrasound* 56, no. 1, 21 May 2014, pp. 9-11. <https://doi.org/10.1111/avr.12179>
- Vezzoni, Aldo, and Kevin Benjamin. "Canine Elbow Dysplasia." *Veterinary Clinics of North America: Small Animal Practice*, vol. 51, no. 3, Mar. 2012, pp. 439-474. <https://doi.org/10.1016/j.cvsm.2020.11.007>
- Shaw, Elaine, and Jeanine Henry. "Radiographic Positioning: Head, Shoulders, Knees, & Toes, Part 1." *Today's Veterinary Nurse*, 26 Oct. 2016. [todayveterinarynurse.com/radiology-imaging/radiographic-positioning-head-shoulders-knees-and-toes-part-1/](https://www.todayveterinarynurse.com/radiology-imaging/radiographic-positioning-head-shoulders-knees-and-toes-part-1/)
- Shaw, Elaine, and Jeanine Henry. "Radiographic Positioning: Head, Shoulders, Knees, & Toes, Part 2." *Today's Veterinary Nurse*, 7 Mar. 2017. [todayveterinarynurse.com/radiology-imaging/radiographic-positioning-head-shoulders-knees-and-toes-part-2/](https://www.todayveterinarynurse.com/radiology-imaging/radiographic-positioning-head-shoulders-knees-and-toes-part-2/)
- van, et al. "Osteochondritis Dissecans of the Tarsus in Labrador Retrievers: Clinical Signs, Radiological Data and Force Plate Gait Evaluation after Surgical Treatment." *Veterinary and Comparative Orthopedics and Fractureology*, vol. 23, no. 01, 2 Jan. 2012, pp. 128-134. <https://doi.org/10.1415/Avort-11-03-0096>
- Osteochondritis Dissecans of the Tarsus in Labrador Retrievers: Clinical Signs, Radiological Data and Force Plate Gait Evaluation after Surgical Treatment. *Veterinary and Comparative Orthopedics and Fractureology*, vol. 23, no. 01, 2 Jan. 2012, pp. 128-134. <https://doi.org/10.1415/Avort-11-03-0096>
- Osteochondritis Dissecans of the Tarsus in Labrador Retrievers: Clinical Signs, Radiological Data and Force Plate Gait Evaluation after Surgical Treatment. *Veterinary and Comparative Orthopedics and Fractureology*, vol. 23, no. 01, 2 Jan. 2012, pp. 128-134. <https://doi.org/10.1415/Avort-11-03-0096>
- Now Salt, et al. "Clinical Manifestations, Response to Treatment, and Clinical Outcome for Weimaraners with Hypertrophic Osteodystrophy: 53 Cases (2009-2011)." *Journal of the American Veterinary Medical Association*, vol. 142, no. 9, 1 May 2012, pp. 1260-1266. <https://doi.org/10.2460/javma.242.9.1260>
- Franklin, Charafel, et al. "Prevalence of Incidental Humeral Intracortical Fractures in Brachycephalic Breed Dogs in CT Studies." *Veterinary Radiology & Ultrasound*, 7 Dec. 2022. <https://doi.org/10.1111/avr.13391>



EMERGENCY



RHONDA DIXON
DVM

Dr. Rhonda Dixon received her doctor of veterinary medicine degree from Texas A&M University in 1999, having previously graduated with a bachelor's degree in biomedical science and animal science from Texas A&M in 1994. Dr. Dixon has practiced emergency/critical care medicine in the Houston and Sugar Land areas for more than 15 years.

Her special interests include trauma medicine, feline medicine, and endoscopy. Time away from work is spent with her wife, their multiple cats/dogs, and a bird. Outside of work, she enjoys watching football, spending time at her lake house in east Texas, and going off road in her 4WD FJ Cruiser.



RHONDA.DIXON@GCVS.COM
713-693-1111

TRIAGE CLASSIFICATION CHART

Triage Classification	Description	Examples:
First Priority	Patient Critical Treatment must be initiated within seconds to minutes	Cardiopulmonary arrest, Major bleeding, breathing problems, altered mentation, shock, history of toxin ingestion, active seizures, anaphylaxis
Second Priority	Patient Urgent Currently stable, but may become 1st priority patient, need to be reassessed, or have treatment initiated within minutes to hours	History of major trauma, history of unsuccessful urination, repeated vomiting or diarrhea, some toxin ingestions, some fever patients
Third Priority	Patient Stable Pressing problem that is non-critical Treatment initiated within hours	Fever, lacerations, open fractures, vomiting, diarrhea (no shock or altered state of mentation)
Fourth Priority	Patient Completely Stable Needs evaluation, requires action in the next 24+ hours	Minor skin issues, ear infections, most limping patients

The Golden Hour

- First 1+ hours after presentation
- Identify life threatening problems and start treatments to mitigate consequences
- BE PROACTIVE
- ANTICIPATE



PATIENT ASSESSMENT

- Started by technician/triage team
 - Quick history; more thorough history later
 - Obtain vitals
- Concurrent assessment by DVM
- ID life threatening problems/injuries
- Airway, Breathing, Circulation, Neurological



AIRWAY



AIRWAY

- Open?
- Obstructed?
- INTUBATION—if you are thinking about it, do it.

BREATHING

- Normal vs labored
- Increased vs decreased rate
- Localization of problem—upper airway vs lower airway vs pleural space vs parenchymal
- Look Alikes/Honorable Mentions
- Always OK to give oxygen



RECOGNIZING RESPIRATORY PATTERNS

UPPER AIRWAY:

- Exaggerated or prolonged inspiration effort with little to no air movement
- O₂ supplementation is not effective, therefore immediate invasive measures are indicated (sedation/anesthesia, intubation, positive pressure ventilation)
- Emergency tracheostomy may be indicated if intubation not feasible
- Laryngeal paralysis, brachycephalic airway obstructive syndrome, collapsing trachea, foreign body, neoplasia



RECOGNIZING RESPIRATORY PATTERNS

SMALL AIRWAY/LOWER AIRWAY

- Wheezes or whistles may be heard
- Most likely to be a cat vs dog
- Cats will present with a pronounced expiratory push, normothermic and normotensive
- Oxygen supplementation, bronchodilators (albuterol inhaler, terbutaline), steroids, sedation?
- Examples: Feline asthma, chronic bronchitis (dog)



RECOGNIZING RESPIRATORY PATTERNS

PLEURAL SPACE DISEASE

- Asynchronous or restrictive pattern
- Dull or absent lung sounds
- TFAST—fluid vs. air vs. organs vs mixture
- Pleural fluid (pyothorax, chylothorax, hydrothorax, neoplasia)
- Air—pneumothorax (trauma, spontaneous)
- Diaphragmatic hernia—recent trauma?





Recognizing Respiratory Patterns

PARENCHYMAL DISEASE

- Diseases that affect the terminal and respiratory bronchioles, interstitium, alveoli, or vasculature of the lung
- Infiltration with microorganisms, inflammatory or neoplastic cells
- Airspaces may be filled with edema, or foreign material
- Or Lung tissue may be replaced by fibrotic tissue
- Examples: Infectious pneumonia, aspiration pneumonia, pulmonary fibrosis, CHF, NCPE, pulmonary contusions, or neoplasia



RECOGNIZING RESPIRATORY PATTERNS


LOOK ALIKE/HONORABLE MENTIONS

- Decreased O₂ delivery—secondary to poor cardiac output
 - Cardiac arrhythmias
 - Hypovolemia
 - Pericardial effusion
- Stress/anxiety/pain
- Reverse Sneeze
- Acid-base disturbances—metabolic acidosis (uremia, ketoacidosis, ethylene glycol intoxication)
- Hyperthermia
- Neurological Disease – intracranial diseases affecting brain stem, or cerebral cortex; Cheyne-Stokes, gasping/chaotic respirations, central neurogenic hyperventilation



OXYGEN DELIVERY METHODS

	FiO ₂ (%)	Flow rate	Advantages	Limitations	Indications
Low flow					
Flow by	20-40	6-8 L/min	<ul style="list-style-type: none"> • Utilizes readily available equipment 	<ul style="list-style-type: none"> • Not appropriate for prolonged therapy • Variable 	<ul style="list-style-type: none"> • Fringe and procedure • Initial stabilization
Oxygen cage	20-40		<ul style="list-style-type: none"> • Will submerge • Allows eating and drinking 	<ul style="list-style-type: none"> • Reduced access to patients • FiO₂ rapidly decreases when doors opened • Larger patients 	<ul style="list-style-type: none"> • Patients that will not tolerate nasal oxygen or in which nasal oxygen is contraindicated
Face mask	35-55	1-4 L/min	<ul style="list-style-type: none"> • Utilizes readily available equipment • Submerging at low rates 	<ul style="list-style-type: none"> • Not appropriate for prolonged therapy • FiO₂ depends on fit of mask 	<ul style="list-style-type: none"> • Fringe and procedure • Initial stabilization • Risk of rebreathing
Nasal prongs		30-130 mL/kg/min	<ul style="list-style-type: none"> • Easy to place • Will submerge 	<ul style="list-style-type: none"> • Poor patient tolerance at high flow rates • Not suitable for acute fluid resuscitation 	<ul style="list-style-type: none"> • Ongoing oxygen support in hospital
Nasal catheter	30-60	30-130 mL/kg/min	<ul style="list-style-type: none"> • Will submerge 	<ul style="list-style-type: none"> • Poor patient tolerance at high flow rates • Harder to place 	<ul style="list-style-type: none"> • Ongoing oxygen support in hospital
High flow					
CPAP	21-100		<ul style="list-style-type: none"> • Delivers FiO₂ • Delivers PEEP • Transmits rebuffed gases 	<ul style="list-style-type: none"> • Often requires heavy sedation • Specific equipment 	<ul style="list-style-type: none"> • Hypotensive despite oxygen support • Upper airway obstruction
HFNO2	21-100	10-60 L/min	<ul style="list-style-type: none"> • Delivers FiO₂ • Delivers PEEP • Transmits rebuffed gases 	<ul style="list-style-type: none"> • Specific equipment 	<ul style="list-style-type: none"> • Hypotensive despite conventional oxygen therapy • Increased work of breathing
Mechanical ventilation	21-100		<ul style="list-style-type: none"> • Delivers FiO₂ • Delivers PEEP • Transmits rebuffed gases 	<ul style="list-style-type: none"> • Specific equipment • High complication rate • High cost 	<ul style="list-style-type: none"> • Hypoventilation • Hypotensive despite oxygen support • Increased work of breathing (target)



High Flow
Oxygen
Therapy



CIRCULATION

Heartrate

MM color

- Can use vulva or prepuce
- CRT

Pulse Quality

Extremity/body temperature

Blood pressure—not sensitive test for diagnosis of shock

- Compensatory shock—will be normotensive



TABLESIDE DIAGNOSTICS DURING TRIAGE ASSESSMENT

VPOCUS(AFAST/TFAST)

BG

LACTATE

PCV/TP

SPO₂

EKG



Shock vs Dehydration

SHOCK

- Tissue hypoperfusion
 - Hypovolemic (hemorrhage, dehydration, 3rd spacing)
 - Distributive/Vasodilatory (sepsis, SIRS, anaphylaxis)
 - Cardiogenic (CHF, arrythmia)

DEHYDRATION

- Loss of water from interstitial space
- Untreated/unresolved dehydration can lead to shock, but they are not interchangeable



HYPOVOLEMIC SHOCK


- Most common shock seen in dogs/cats
- Dogs tend to have more predictable progressive changes in their cardiovascular status in response to volume depletion
 - heart rate
 - mucous membranes color
 - capillary refill time
 - pulse pressure profile
- Hemorrhage, fluid losses (e.g., from GI tract) or third spacing
- Goal of therapy is to restore perfusion by increasing intravascular volume



CARDIOGENIC SHOCK

- Results in a low-forward flow state due to cardiac derangements
 - Poor myocardial contractility
 - Poor preload
- Examples:
 - DCM
 - HCM
 - Valvular Disease
 - Pericardial Tamponade
 - Severe arrhythmias
- Important to identify because it is NOT treated by fluid resuscitation
 - Patients can look very similar to patients in hypovolemic shock
 - Hallmarks: Murmur, arrhythmia, pulmonary edema, ascites, respiratory distress





NEUROLOGICAL STATUS

- MENTATION
 - Alert
 - Obtunded
 - Stuporous
 - Comatose
- MOTOR FUNCTION/GAIT/BALANCE
- CRANIAL NERVES
 - Pupil size—equal vs anisocoria
 - Menace Response
 - Facial sensation



NEUROLOGICAL STATUS

- VESTIBULAR DISEASE
 - Rolling behavior, ataxia, head tilt, nystagmus
- DULL OR COMATOSE: Could indicate serious intracranial disease
- OPISTHOTONUS POSTURE (stiff forelimbs and head extended)-- increased cranial pressures
- NON-AMBULATORY (paresis or paralysis)
 - Trauma?
 - IVDD?
 - Neoplasia of spinal cord



A FEW POINTS TO REMEMBER


- During TRIAGE, patients should be re-assessed frequently
- Determine response to treatment
 - Monitor for decompensation and need for more emergent intervention

HYPOVOLEMIC SHOCK— Most common in dogs/cats

CARDIOGENIC SHOCK-- Important to identify because it is NOT treated by fluid resuscitation

- Patients can look very similar to patients in hypovolemic shock

SECONDARY ASSESSMENT—more thorough PE after life threatening issues have been addressed



ANESTHESIA



KATHARINE MCIVER
DVM



KATHARINE.MCIVER@GCVS.COM
713-693-1111

Pain Management

Katharine A. McIver, DVM, MPH

August 2023

GCVS.COM

Pain Management

Objectives



- Pain physiology and pathophysiology
- Acute pain
- Chronic pain
- Pharmacological intervention of pain
- Non-pharmacologic modalities for pain
- Closing thoughts



2

Pain :

An unpleasant sensory and emotional experience associated with actual or potential damage, or described in terms of such damage

Nociception :
Neuronal process of encoding noxious stimuli

Lumb and Jones et al. *Veterinary Anesthesia and Analgesia* 5th Edition, Ames Iowa, 2015

Physiology

Types of Pain

- **Temporal**
 - Acute vs chronic
- **Physiological**
 - Peripheral vs central
 - Inflammatory vs neuropathies
 - Physical damage vs nerve damage
- **Somatic vs visceral**
 - Well localized vs poorly localized

Physiology


Nociceptors

- Free endings on primary sensory neurons
- Detect signals from damaged tissue
- Found in skin, muscle, joints, bones, and viscera
 - Not present in the CNS
- Several categories of nociceptors
 - Mechanical
 - Thermal
 - Chemical
 - Polymodal
 - Silent

Physiology

Nociceptors

- **Several factors activate nociceptors**
 - Damaged tissues release a variety of substances from lysed cells
 - New substances are made at the site of injury
- **Nociception has a minimum threshold and is not an all or none**
 - Increased stimulation = increased sensation of pain
- **The release of local inflammatory factors can cause sensitization**



Physiology

Acute Pain

- **Acute pain is caused from the following:**
 - Surgery, traumatic injury, tissue damage, and inflammatory processes
- **Useful biological purpose with a rapid onset**
- **Can be self-limiting and should be resolved ≤ 3 months**
- **Treatment of acute pain:**
 - Interrupting nociceptive signals and treating the underlying cause
- **Inadequate controlled of acute pain can be a factor in the development of chronic pain**

Physiology

Chronic Pain

- Pain that is present for >6 month
- Pain that continues after the initial injury or illness has healed
- Chronic pain can be considered a disease
- Chronic pain has no biological purpose
- Requires a multidisciplinary approach
- Often time requires more than one therapeutic modality
- Complex and frustrating

Pharmacological Treatment

- Alpha- 2 adrenergic receptor agonist
- Local anesthetics
- N-Methyl-D-aspartate receptor antagonist (NMDA)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Opioids
- Adjunctive analgesics
 - Gabapentin
 - Neurokinin (NK)-1 receptor antagonists
 - Cannabis
 - Others

Pharmacological Treatment

Alpha-2 Agonist

- **Wide range of effects on the body**
 - Cardiovascular, respiratory, central nervous system, endocrine, GI, urogenital
- **Dexmedetomidine is alpha-2 agonist of choice**
- **Site of analgesic activity**
 - Peripherally
 - Spinally and supraspinal
 - Induces action via the presynaptic terminal of primary afferent neurons
 - Direct inhibition of spinal cord neurons

Pharmacological Treatment


Dexmedetomidine

- Pre-medication 0.5-2.0 mcg/kg IV or IM
- Post-operative analgesia 0.5-2.0 mcg/kg IV
- Can run as a CRI
 - 0.5-2.0 mcg/kg/hr
- Reversible drug
 - Will reverse the analgesia
- Works synergistically with opioids
- Caution in patients with decreased cardiovascular function

Pharmacological Treatment

Local Anesthetics

- Prevents nociceptive transmission
- Can produce dose dependent anti-inflammatory effects
- May reduce free radical formation
- Good for visceral pain






<https://www.bcm.edu/research/fabs/matthew-rasband>

Pharmacological Treatment

Local Anesthetics

- Lidocaine
 - Loading dose 2mg/kg
 - CRI 25-35 mcg/kg/min
 - Nerve block 1-2mg/kg
- Bupivacaine/ Ropivacaine
 - Peripheral nerve block 1-2mg/kg
 - Epidural 0.8mg/kg
 - Never give IV
- Local anesthetic doses are additive
- Toxic effects seen at 8mg/kg in dogs and 6mg/kg in cats

	Molecular Weight	Distribution Coefficient
	288	346
	274	115
	234	43

<http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1947380>

Pharmacological Treatment

Local Anesthetics


- **Liposomal Bupivacaine → Nocita®**
 - Up to 72 hours of pain control
 - Dose is 5.3mg/kg
 - Can dilute with NaCl 0.9%
 - FDA approved
 - TPLO in dogs
 - Onychectomy in cats



Pharmacological Treatment

N-Methyl-D-aspartate receptor antagonist


- **Ketamine**
 - Somatic pain >> visceral
 - Adjunctive analgesia
 - Loading dose 1-2 mg/kg
 - CRI 0.5-0.8 mg/kg/hr
 - Potential side effects



Pharmacological Treatment

N-Methyl-D-aspartate receptor antagonist

- **Amantadine**
 - Oral NMDA antagonist
 - Can be helpful with chronic pain
 - Can take up to 21 days to be effective
 - Dogs and cats 3-5mg/kg PO q. 12
- **Methadone**
 - Opioid with NMDA antagonist properties
 - Works synergistically with other drugs
 - Less hyperthermia in cats
 - More consistent sedation when compared to hydromorphone



Pharmacological Treatment

Non-Steroidal Anti-Inflammatory

- Decrease COX enzyme conversion
 - Mild reduction of central pain transmission
- Non-controlled substance
- Oral and injectable forms
- Standard medication after elective procedures
- Avoid in patients with:
 - Dehydration, hypovolemia, and hypotension
 - Certain renal, hepatic, and cardiovascular insufficiency
- Use with caution in patients:
 - Receiving corticosteroids, aminoglycosides, and polymyxins, furosemide, and ACEi

Pharmacological Treatment

Acetaminophen

- Potential central mediation of COX-3
- Possible activation of serotonin receptors
- K9 studies does not produce anti-inflammatory but, is an effective analgesic
- Can cause liver toxicities therefore monitor liver values
- Often combined with codeine
- Dogs 15mg/kg PO q. 8
- **DO NOT USE IN CATS**

Pharmacological Treatment

Pure Mu Opioids

- **Morphine**
 - 2-4 hour intra-op duration
 - Administer slowly IV (histamine release)
- **Hydromorphone**
 - 1-2 hour intra-op duration
- **Methadone**
 - 2-4 hour intra-op duration
 - NMDA antagonist activity
 - Least likely to cause vomiting
- **Fentanyl – Remifentanyl**
 - 15 – 30 min and 6 min duration respectively
 - Usually administered as a CRI

★ Different Potency but Equal Efficacy!

Pharmacological Treatment

Mixed Opioids

- **Buprenorphine**
 - ~ 45 min intra-op duration
 - Partial mu agonist
 - Preferential binding
 - "Ceiling effect"
- **Butorphanol**
 - ~ 30-60 min duration
 - Kappa agonist and mu antagonist
 - May be used to reverse pure mu opioid incase of overdose

Pharmacological Treatment

Reversal

- **Naloxone**
 - Used to reverse all opioids
 - ~ 30- 60 min duration
 - Redosing may be necessary in long-acting opioids
 - May be used incases of opioid dysphoria
 - Administer via titration to avoid acute pain
 - 0.02 mg diluted into 5 ml sterile saline
 - Administer in 1 ml increments until desired effect achieved

Pharmacological Treatment

Oral Opioids for post-op pain

- **Codeine**
 - Low oral bioavailability
- **Tylenol 3**
 - Acetaminophen + codeine
 - Schedule III drug
- **Tramadol**
 - Low efficacy in dogs and horses
 - Good efficacy in cats – tastes bitter

Pharmacological Treatment

Gabapentin

- Structurally similar to inhibitory neurotransmitter GABA
- Not an agonist and does not effect GABA uptake or degradation
- Presynaptic inhibition of calcium channels
- Neuropathic pain treatment
- Great adjuvant with NSAID
- Can take several days to establish effectiveness
- Dogs 10-20 mg/kg PO q. 6-8 hr
 - Need frequent dosing due to short half life
- Cats 5-10 mg/kg PO q. 8-12 hr

Pharmacological Treatment

Maropitant

- Neurokinin (NK)-1 Receptor Antagonist
- Blockade of substance P
- NK-1 receptors have been identified in the CNS and PNS

Pharmacological Treatment

Cannabidiol

- Difficult to know the purity of products and exact CBD concentrations
- Peak Performance Veterinary Group – Colorado
- CBD concentration 100mg/mL
 - Has additional cannabidiol substances
 - www.peakvets.com
- Google CHO pet
- Current dose recommendations 0.02 - 0.1mg/kg PO q. 12
 - Half life is about 200 minutes
- Has caused increases in ALP
- Seems oil based products have better pharmacokinetics

Non-Pharmacological Pain management

- Weight optimization
- Acupuncture
- Physical rehabilitation
- Thermal modification
- Environmental modifications
- Chiropractic care
- Homeopathy

Closing Thoughts

- Preparation for addressing pain : surgical or trauma
 - Can I sedate this patient?
 - Can I give an NSAID?
 - Can I provide a peripheral nerve block and or an epidural?
- Choose an appropriate analgesia
 - Bolus or CRI
- Additional analgesic CRIs
 - Lidocaine
 - Ketamine
 - Dexmedetomidine
 - Additional opioid



SURGERY




NATHAN SQUIRE **VMD, MS, DACVS-SA**

Dr. Nathan Squire obtained his Veterinariae Medicinae Doctoris (VMD) from the University of Pennsylvania in 2017, before traveling to Tufts University for a rotating internship in medicine and surgery. From there, he headed south to the Veterinary Orthopedic and Sports Medicine Group for a surgical internship, before heading south yet again to the University of Tennessee for a 3-year residency in small animal surgery, during which he also earned his Master of Science degree.

Dr. Squire's surgical interests include minimally invasive surgery (including soft tissue and orthopedic procedures), fracture repair, and joint replacement.



NATE.SQUIRE@GCVS.COM
713-693-1111



Quadriceps mechanism

- Quadriceps = “four headed”
 - **Rectus femoris** – originates on ventral ilium
 - **Vastus medialis, lateralis, and intermedius** – originate on proximal femur
- Common tendinous insertion on patella





Quadriceps mechanism

- **Patellar tendon**
- **Patella**
 - Sesamoid bone within tendon of insertion
- **Patellar ligament**
- **Tibial tuberosity**
 - Insertion composed of Sharpey's fibers
 - Separate ossification center in juveniles (closure typically at 10-12 months)



Quadriceps mechanism

- **Trochlear groove** of the femur
 - Area between femoral condyles in which patella should glide
 - Covered by articular cartilage
- **Tibial tuberosity**



Objectives

- Anatomy review
 - Quadriceps mechanism
- **Predisposing factors**
- Clinical signs and diagnostics
- Management
 - Surgical vs conservative
- Complications



Developmental condition

- Patellar luxation typically *not* present at birth, but predisposing factors often *are*
- Medial patellar luxation is the most common form, regardless of dog size¹
 - Medial, lateral, or bi-directional possible




“Q-angle”

- Quantitative measure of deviation of quadriceps mechanism
- Directly related to horizontal force of quadriceps on patella
- In unaffected dogs, average reported is 10.5° (+/- 5.6°)¹
- **Increase in Q angle** can result in *medial* patellar subluxation or luxation²



What causes increased Q-angle?

- Coxa vara
- Distal femoral varus
- Medial femoral condylar hypoplasia
- Internal rotation of the tibia
- Medial displacement of the tibial tuberosity
- Internal rotation of the hock



Development

- During skeletal growth, trochlear groove develops secondary to pressure from patella
- Patellar luxation can lead to shallow/absent trochlear groove and hypoplasia of one or both of the femoral trochlear ridges
 - Predisposes to further or more severe luxation



Traumatic patellar luxation

- Can also occur secondary to trauma – much less common
 - Frequently entails damage to medial or lateral parapatellar joint capsule/fascia
 - Reported to occur in 18% of cases of patellar luxation³



Grading system

- Grade IV
 - Permanent, non-reducible patellar luxation
 - If not corrected early, will lead to severe skeletal abnormalities, making repair challenging
 - Tibia often rotated 60-90 degrees
- Clinical signs:
 - Similar to grade III luxations
 - More likely to have persistent gait changes, such as “crouched” stance
- “Out-out”



Grade IV MPL



Acute onset lameness?

- **CHECK FOR CCL RUPTURE!!**
 - Also consider potential for traumatic patellar luxation
 - May be accompanied by asymmetric subcutaneous swelling
 - Concurrent CCLR present in 15-20% of mature dogs with MPL⁴
- ****When assessing for tibial thrust or cranial drawer, important to reduce patella first**
- Stifle effusion often more severe with CCLR +/- meniscal injury



Orthopedic Exam

- Performed with animal standing, then in lateral
- Can trace patellar ligament from tibial tuberosity to isolate patella
- MPL typically demonstrated by:
 - Internally rotating tibia
 - Flexing stifle – often a “popping” sensation palpated
 - Extending stifle
- Palpation of trochlear groove to note depth/erosion
- Check for tibial thrust and cranial drawer



Diagnostics

- Orthogonal stifle radiographs sufficient for low-grade luxations
 - Patella may reduce spontaneously during positioning
- Higher grade (III or IV) with concurrent skeletal abnormalities:
 - Consider independent, orthogonal views of femur and tibia
 - CT scan with 3-D reconstruction highly useful for angular deformities and surgical planning



Brower et al, 2016



Objectives

- Anatomy review
 - Quadriceps mechanism
- Predisposing factors
- Clinical signs and diagnostics
- **Management**
 - Surgical vs conservative
- Complications



To cut or not to cut?

- Grade I
 - Surgery not indicated
 - Continue to monitor for clinical signs, reevaluate if noted
- Grade II?
 - Degree/frequency of lameness, progression of OA, \$\$ commitment
- Grade III or IV
 - Early surgical intervention indicated to prevent progressive skeletal abnormalities and osteoarthritis
- Concurrent stifle pathology (e.g. CCLR)
- Immature patients?
 - Staged procedures possible, with early interventions aimed at sparing physes



Conservative management

- Weight loss
- Joint supplements
 - Glucosamine and chondroitin sulfate
 - Omega-3 fatty acids
- +/- analgesics as needed
 - NSAID (Carprofen, meloxicam, Onsior), gabapentin
 - Methocarbamol if muscle spasm suspected
- Can consider joint injections in later stages of refractory OA



Surgical management

- Goals:
 - Restore alignment of quadriceps mechanism
 - Restore (or create) functional trochlear groove of femur
- Typically entails both bony and soft tissue reconstruction



2023 SPONSOR DIRECTORY

PLATINUM SPONSORS



Barry Cannon

bcanon@brownsmedicalimaging.com

727-215-8242

brownsmedicalimaging.com

Brown's Medical Imaging has specialized in the sales and service of medical imaging equipment for over 25 years. Offering new and remanufactured CT, MRI and Digital X-ray systems for the veterinary community. Equipment available for both large and small animal applications. ISO certified remanufacturing of CT and MRI systems.



Jon Eric Bjorling

jon.bjorling@petmeadow.com

Pet Meadow

Pet Cremation and Memorial Services

At Texas Pet Meadow, we give families peace of mind through true private pet cremation and aftercare services located in Houston, TX.

2023 SPONSOR DIRECTORY

PLATINUM SPONSORS



Lauren Stanaland
lauren.stanaland@zoetis.com
zoetis.com

At Zoetis, our purpose is to nurture our world and humankind by advancing care for animals.

OUR HISTORY



Founded in 1995 and headquartered in Omaha, Brown's Medical Imaging (BMI) is a family-owned and operated company specializing in the sales and service of medical imaging equipment for over 25 years. Personalized customer attention is a longstanding BMI tradition and the cornerstone of our business philosophy.

WARRANTY



5-Year Warranty

Included with the purchase of any Fujifilm Supria 32 Plus, Supria True64 CT, or Accogent Pausch at the 2023 Gulf Coast Veterinary Specialists Symposium.

IMAGING SOLUTIONS



Everything Your Practice Needs

We offer a comprehensive selection of veterinary imaging equipment for sale. From digital radiography to ultrasound, CT scans, and MRI, we have everything you need. Find the right tools to enhance your veterinary practice with our top-notch equipment.



Scan to learn more!

CONTACT US

sales@brownsmedicalimaging.com
1 (800) 524-7166

Raising the Standards in Pet Cremations

***On average, we save clinics
at least 20% on
cremation and aftercare services.***

- ***100% True Private Cremation***
- ***Guaranteed 24-Hour Telephone Support***
- ***No ambiguous service fees***
- ***Open 7 days a week***
- ***Witness Services available***
- ***Highest Industry Accreditation***



For more information please contact:
Cody Coke - cody.coke@petmeadow.com



Pet Meadow

Pet Cremation & Aftercare Services

Texas Pet Meadow

14355 Spencer Rd (FM Rd 529) HOUSTON, TX 77095

**Contact Us by Phone 24hrs:
(713) 823-1002**

www.petmeadowtexas.com

Librela[®]
(bedinvetmab injection)

Librela is the **First and Only Monthly Injectable Anti-NGF Monoclonal Antibody Therapy** for the Control of Canine Osteoarthritis (OA) Pain



Effectively controls canine OA pain with a monthly injection



Approved as safe and functions like naturally occurring antibodies with minimal metabolism by the liver or kidneys³



Works differently than NSAIDs by reducing NGF effects, a key factor in canine OA pain⁴⁻⁶



Reduced canine OA pain, which led to increased activity and improved quality of life^{1,7-9*}

*Results from clinical studies conducted in the US and EU.^{1,9}
NGF=nerve growth factor; NSAID=nonsteroidal anti-inflammatory drug.



Scan the QR Code to learn more at LibrelaVetTeam.com.

2023 SPONSOR DIRECTORY

GOLD SPONSORS



Rebecca Kramer

rebecca@bcpvetpharm.com

713-771-1144

bcpvetpharm.com

BCP Veterinary Pharmacy is the ORIGINAL animal only compounding pharmacy customizing dosages and tailoring flavors to make medicating your pets a treat. We are pharmacist owned and our new pricing and vast product availability makes us your one stop shop for compounded meds!



Kyle Herbst

kyle.herbst@dechra.com

210-393-5394

dechra-us.com

Dechra has a long history in the veterinary health market, and has grown into a global veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. We continue to grow because we understand the challenges veterinarians face. We provide training, support and information that helps them help animals, as well as accessible science that enables vets to communicate with owners and farmers better. It's this perspective that makes us a preferred supplier`

2023 SPONSOR DIRECTORY

GOLD SPONSORS



Michael Moreau

michael.moreau@royalcanin.com
royalcanin.com

Health is something different for every pet, at Royal Canin we create tailored nutrition that helps cats and dogs live their healthiest lives.



Zach Walsh

zach.walsh@scribeamerica.com
954-228-7765

ScribeAmerica is the standard in professional scribe training and management. By continuing to innovate and expand the scribe industry we will fundamentally improve the delivery of care and quality of life for medical providers nationwide. Together, we can revolutionize how patient care is delivered.

BCP COMPOUNDS IT ALL

TASTY FLAVOR CHEWS &
SUSPENSIONS

TRANSDERMAL GELS &
TOPICALS

STERILE

PRODUCTS
CAPSULES

INJECTABLES



BCP
VETERINARY
PHARMACY

WE CARRY AND SOURCE THE
MEDICATIONS YOU NEED



ScribeAmerica

**VETERINARY
SCRIBES**

Booth #9

- ✓ Focus on the Patient
- ✓ Reduce Overtime & Burnout
- ✓ Improved Charting
- ✓ In-Person, Virtual, & AI Solutions



**WIN A NEW
PUTTER!**

DAY IN. DAY OUT. YOU WORK, WORK, WORK.



Reliable solutions for your
veterinary team. That work.

To order, please contact your Dechra or distributor
representative or call (866) 683-0660.

CAUTION: Federal law restricts these drugs to use by or
on the order of a licensed veterinarian.
Full prescribing information is available at www.dechra-us.com.

Dechra is a registered trademark of Dechra Pharmaceuticals PLC.
Dexmedetomidine, Isospire, Torphadine and Tzed are trademarks of Dechra Veterinary Products, LLC.
Zenalpha is a registered trademark of Dechra Limited; all rights reserved.
© 2023 Dechra Veterinary Products. C230185



PRACTICE HEALTH PORTFOLIO

Nutrition Rx & Dx Support



STAY CURIOUS

CURIOSITY IS ASKING QUESTIONS TO
UNDERSTAND YOUR PATIENTS' NEEDS.
HEALTH IS UNCOVERING THE ANSWERS.

As cats grow and mature, they become experts
at hiding signs of diseases, like feline lower
urinary tract disease (FLUTD)— a condition
that reoccurs in 50% of the cats it affects.¹
Royal Canin® tailored nutrition solutions and
at-home screening tools provide the answers
you need to deliver proactive care for
improved health outcomes.

- Specialized screening and monitoring products, like Royal Canin Hematuria Detection, technology by BLÜcare, can shorten the time between at-home detection and proactive in-clinic treatment.**
- Exclusive access to our continuing education tools will help you navigate the ever-changing cat treatment landscape and deliver quality care for years to come.**



**SPARK
YOUR
CURIOSITY**
Visit the
Royal Canin booth
to learn more.

Visit my.royalcanin.com/vet/urinary

REFERENCE: 1. Forrester SO. 2004.



2023 SPONSOR DIRECTORY

SILVER SPONSORS

Antech

Paul Torp
paul.torp@antech.com
antechdiagnostics.com

Trupanion

Sydney Castillo
sydney.castillo@trupanion.com
713-253-9988

Care Credit

Martin Normand
mnormand@carecredit.com

IDEXX

Megan Cenicola
megan-cenicola@idexx.com
857-413-7350

Elanco

Jenny Bennett
jenny.bennett@elancoah.com

Nutramax

Averi Woodard
awoodard@nutramaxlabs.com
816-273-9755

Fond Memories Pet Crematorium

Matt Mayton
mmayton@fondmemories.com

On Hold Marketing

Robert Younger
ry@onholdmarketingworks.com

Hills Pet Nutrition

Maj Angarano, DVM
maj_angarano@hillspet.com
817-455-7214
www.hillspet.com

Specialty Veterinary Pharmacy

Isaac Garcia
713-380-7912
isaac.garcia@svpmeds.com

Movora

Mollie Ford
mollie.ford@movora.com

Virbac




Charles Ganzzino
charles.ganzzino@virbacus.com
818-216-4754

Veterinary Anesthesia Support Service

Carrie Junge
carrie@vasservice.com
800-498-5575



Your Texas Compounding Pharmacy

-  Quality Medication at Affordable Prices
-  Fastest Turnaround in Texas
-  100% Patient Compliance

877-673-3705
SVPMEDS.COM



30 YEARS OF UNMATCHED QUALITY
nutramax LABORATORIES

Booth #19

-  JOINT
-  LIVER
-  GASTROINTESTINAL
-  DENTAL HEALTH
-  SKIN & COAT
-  URINARY
-  RENAL



Visit booth #19 for the show special
Averi Woodard
awoodard@nutramaxlabs.com

OUR MISSION IS TO SERVE THE LORD AND GLORIFY HIM USING THE GIFTS HE HAS GIVEN OUR EMPLOYEES TO RESEARCH, DEVELOP, MANUFACTURE, AND MARKET PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PEOPLE AND THEIR PETS.



Tap into decades of expertise from the Movora family of brands through our broad portfolio of surgical products and quality instruments.



Visit Movora in the exhibit hall or online at movora.com!

trupanion™
Medical insurance for the life of your pet.

We can pay your hospital directly at checkout!

Because Trupanion can pay our share of an invoice directly to any hospital at checkout, pet parents can more easily say 'yes!' to the treatment their pet needs.

Learn why over 1 million pet parents have chosen us to pay their invoice!





Budget-friendly financing for veterinary care is friendlier than ever.

Learn More




© 2023 Synchrony Bank

OnHold Marketing

713.594.9136

onholdmarketingworks.com

The preferred message on-hold provider by leading veterinary practices!



Introducing your friend in the fight — powerful nutrition designed for dogs with cancer.

NEW

ONC CARE

Support & Support

VETERINARIAN RECOMMENDED

SCIENCE DID THAT.

Highly Recommended

WE ARE A PROUD LEADING VETERINARY ANESTHESIA SERVICE & EQUIPMENT PROVIDER

Veterinary Anesthesia Support & Service

'HEAD TO TAIL' MACHINE SERVICE ↔ EXPERIENCED STAFF ↔ LARGE SERVICE TERRITORY

WE'D LOVE TO HEAR FROM YOU! 800-498-5575 WWW.VASSERVICE.COM INFO@VASSERVICE.COM

2023 SPONSOR DIRECTORY

NICKEL SPONSORS

Nova Biomedical

Keith Simpson

ksimpson@novabio.com

830-463-9128

novabiomedical.com

Veterinary Books By Success Concept

Jed Hughes

jedhughes@rocketmail.com

ROO

Saul Lara

saul.lara@roo.vet

510-595-3416

roo.vet

Wedgewood Pharmacy

Mike Wiley

mwiley@wedgewoodpharmacy.com

512-525-9064

Torigen Pharmaceuticals

Larissa Czupik

larissa@torigen.com

937-716-9944

torigen.com